LHC (LHCG) 10-Q3 Nov 222022 Q3 Quarterly reportFinancial data

Company Profile

Cover page

Cover page - shares	9 Months Ended
Cover page - shares	Sep. 30, 2022	Nov. 01, 2022
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2022
Document Transition Report	false
Entity File Number	001-33989
Entity Registrant Name	LHC Group, Inc
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	71-0918189
Entity Address, Address Line One	901 Hugh Wallis Road South
Entity Address, City or Town	Lafayette
Entity Address, State or Province	LA
Entity Address, Postal Zip Code	70508
City Area Code	337
Local Phone Number	233-1307
Title of 12(b) Security	Common Stock, par value of $0.01
Trading Symbol	LHCG
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		31,033,002
Amendment Flag	false
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q3
Entity Central Index Key	0001303313
Current Fiscal Year End Date	--12-31

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Current assets:
Cash	$ 10,522	$ 9,809
Receivables:
Patient accounts receivable	331,524	348,820
Other receivables	30,217	13,780
Total receivables	361,741	362,600
Prepaid income taxes	19,303	7,531
Prepaid expenses	23,128	28,401
Other current assets	25,687	24,801
Total current assets	440,381	433,142
Property, building and equipment, net of accumulated depreciation of $110,600 and $98,394, respectively	153,806	153,959
Goodwill	1,750,420	1,748,426
Intangible assets, net of accumulated amortization of $22,865 and $19,152, respectively	395,309	400,002
Operating lease right of use asset	108,975	113,399
Other assets	65,263	46,693
Total assets	2,914,154	2,895,621
Current liabilities:
Accounts payable and other accrued liabilities	108,748	98,118
Salaries, wages, and benefits payable	84,412	100,532
Self-insurance reserves	38,734	33,784
Contract liabilities - deferred revenue	4,840	106,489
Current operating lease payable	36,998	37,630
Amounts due to governmental entities	2,499	5,447
Current liabilities - deferred employer payroll tax	26,790	26,790
Total current liabilities	303,021	408,790
Deferred income taxes	87,661	70,026
Income taxes payable	7,988	7,320
Revolving credit facility	738,000	661,197
Long-term operating lease liabilities	74,992	78,688
Total liabilities	1,211,662	1,226,021
Noncontrolling interest — redeemable	16,978	17,501
Commitments and contingencies
LHC Group, Inc. stockholders’ equity:
Preferred stock – $0.01 par value; 5,000,000 shares authorized; none issued or outstanding	0	0
Common stock — $0.01 par value; 60,000,000 shares authorized; 36,733,790 and 36,549,524 shares issued, and 30,587,735 and 30,634,414 shares outstanding, respectively	367	365
Treasury stock — 6,146,055 and 5,915,110 shares at cost, respectively	(195,447)	(164,790)
Additional paid-in capital	997,115	979,642
Retained earnings	798,372	751,025
Total LHC Group, Inc. stockholders’ equity	1,600,407	1,566,242
Noncontrolling interest — non-redeemable	85,107	85,857
Total stockholders' equity	1,685,514	1,652,099
Total liabilities and stockholders' equity	$ 2,914,154	$ 2,895,621

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Property, building and equipment, accumulated depreciation	$ 110,600	$ 98,394
Accumulated amortization	$ 22,865	$ 19,152
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	60,000,000	60,000,000
Common stock, shares issued (in shares)	36,733,790	36,549,524
Common stock, shares outstanding (in shares)	30,587,735	30,634,414
Treasury stock at cost, shares (in shares)	6,146,055	5,915,110

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF INCOME - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Income Statement [Abstract]
Net service revenue	$ 576,913	$ 565,451	$ 1,724,601	$ 1,636,193
Cost of service revenue (excluding depreciation and amortization)	347,772	343,862	1,052,093	972,006
Gross margin	229,141	221,589	672,508	664,187
General and administrative expenses	189,051	176,444	569,800	506,754
Impairment of intangibles and other	2,059	0	4,130	937
Operating income	38,031	45,145	98,578	156,496
Interest expense	(9,053)	(1,135)	(19,631)	(1,541)
Income before income taxes and noncontrolling interest	28,978	44,010	78,947	154,955
Income tax expense	6,966	10,150	17,014	32,909
Net income	22,012	33,860	61,933	122,046
Less net income attributable to noncontrolling interests	4,703	6,126	14,586	22,010
Net income attributable to LHC Group, Inc.’s common stockholders	$ 17,309	$ 27,734	$ 47,347	$ 100,036
Earnings per share:
Basic (usd per share)	$ 0.57	$ 0.89	$ 1.55	$ 3.21
Diluted (usd per share)	$ 0.56	$ 0.88	$ 1.55	$ 3.18
Weighted average shares outstanding:
Basic (in shares)	30,565	31,238	30,527	31,205
Diluted (in shares)	30,706	31,434	30,639	31,422
Revenue, Product and Service [Extensible List]	Service [Member]	Service [Member]	Service [Member]	Service [Member]
Cost, Product and Service [Extensible List]	Service [Member]	Service [Member]	Service [Member]	Service [Member]

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) $ in Thousands		Total	Common Stock	Treasury	Additional Paid-In Capital	Retained Earnings	Noncontrolling Interest Non Redeemable
Beginning balance at Dec. 31, 2020		$ 1,613,354	$ 364	$ (69,011)	$ 962,120	$ 635,297	$ 84,584
Beginning balance, Common stock (in shares) at Dec. 31, 2020			36,355,497
Beginning balance, Treasury stock (in shares) at Dec. 31, 2020				5,215,657
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	[1]	39,128				34,659	4,469
Noncontrolling interest distributions		(2,417)					(2,417)
Nonvested stock compensation		3,513			3,513
Issuance of vested stock		1	$ 1
Issuance of vested stock (in shares)			148,447
Treasury shares redeemed to pay income tax		(9,541)		$ (9,541)
Treasury shares redeemed to pay income tax (in shares)				51,221
Purchase of additional controlling interest		(142)			(81)		(61)
Sale of noncontrolling interest		138
Issuance of common stock under Employee Stock Purchase Plan (in shares)			3,204
Issuance of common stock under Employee Stock Purchase Plan		649			649
Ending balance at Mar. 31, 2021		1,644,683	$ 365	$ (78,552)	966,201	669,956	86,713
Ending balance, Common stock (in shares) at Mar. 31, 2021			36,507,148
Ending balance, Treasury stock (in shares) at Mar. 31, 2021				5,266,878
Beginning balance at Dec. 31, 2020		1,613,354	$ 364	$ (69,011)	962,120	635,297	84,584
Beginning balance, Common stock (in shares) at Dec. 31, 2020			36,355,497
Beginning balance, Treasury stock (in shares) at Dec. 31, 2020				5,215,657
Ending balance at Sep. 30, 2021		1,716,193	$ 365	$ (80,605)	974,680	735,333	86,420
Ending balance, Common stock (in shares) at Sep. 30, 2021			36,540,219
Ending balance, Treasury stock (in shares) at Sep. 30, 2021				5,276,834
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income attributable to noncontrolling interest-redeemable		9,100
Beginning balance at Mar. 31, 2021		1,644,683	$ 365	$ (78,552)	966,201	669,956	86,713
Beginning balance, Common stock (in shares) at Mar. 31, 2021			36,507,148
Beginning balance, Treasury stock (in shares) at Mar. 31, 2021				5,266,878
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	[1]	42,875				37,643	5,232
Noncontrolling interest distributions		(4,660)					(4,660)
Nonvested stock compensation		3,993			3,993
Issuance of vested stock (in shares)			15,531
Treasury shares redeemed to pay income tax		(1,213)		$ (1,213)
Treasury shares redeemed to pay income tax (in shares)				6,024
Purchase of additional controlling interest		(1,598)			(870)		(728)
Issuance of common stock under Employee Stock Purchase Plan (in shares)			3,152
Issuance of common stock under Employee Stock Purchase Plan		573			573
Ending balance at Jun. 30, 2021		1,684,653	$ 365	$ (79,765)	969,897	707,599	86,557
Ending balance, Common stock (in shares) at Jun. 30, 2021			36,525,831
Ending balance, Treasury stock (in shares) at Jun. 30, 2021				5,272,902
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	[1]	30,916				27,734	3,182
Noncontrolling interest distributions		(5,052)					(5,052)
Nonvested stock compensation		4,211			4,211
Issuance of vested stock (in shares)			10,943
Treasury shares redeemed to pay income tax		(840)		$ (840)	0
Treasury shares redeemed to pay income tax (in shares)				3,932
Sale of noncontrolling interest		1,650			(83)		1,733
Issuance of common stock under Employee Stock Purchase Plan (in shares)			3,445
Issuance of common stock under Employee Stock Purchase Plan		655			655
Ending balance at Sep. 30, 2021		1,716,193	$ 365	$ (80,605)	974,680	735,333	86,420
Ending balance, Common stock (in shares) at Sep. 30, 2021			36,540,219
Ending balance, Treasury stock (in shares) at Sep. 30, 2021				5,276,834
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income attributable to noncontrolling interest-redeemable		2,900
Beginning balance at Dec. 31, 2021		$ 1,652,099	$ 365	$ (164,790)	979,642	751,025	85,857
Beginning balance, Common stock (in shares) at Dec. 31, 2021		36,549,524	36,549,524
Beginning balance, Treasury stock (in shares) at Dec. 31, 2021		5,915,110		5,915,110
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	[2]	$ 22,214				19,454	2,760
Noncontrolling interest distributions		(2,970)					(2,970)
Nonvested stock compensation		4,376			4,376
Issuance of vested stock		2	$ 2
Issuance of vested stock (in shares)			132,651
Treasury shares redeemed to pay income tax		(3,140)		$ (3,208)	68
Treasury shares redeemed to pay income tax (in shares)				23,022
Repurchase of common stock		$ (25,472)		$ (25,472)
Repurchase of common stock (in shares)				190,622
Issuance of common stock under Employee Stock Purchase Plan (in shares)		5,353	5,353
Issuance of common stock under Employee Stock Purchase Plan		$ 698			698
Ending balance at Mar. 31, 2022		1,647,807	$ 367	$ (193,470)	984,784	770,479	85,647
Ending balance, Common stock (in shares) at Mar. 31, 2022			36,687,528
Ending balance, Treasury stock (in shares) at Mar. 31, 2022				6,128,754
Beginning balance at Dec. 31, 2021		$ 1,652,099	$ 365	$ (164,790)	979,642	751,025	85,857
Beginning balance, Common stock (in shares) at Dec. 31, 2021		36,549,524	36,549,524
Beginning balance, Treasury stock (in shares) at Dec. 31, 2021		5,915,110		5,915,110
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Treasury shares redeemed to pay income tax (in shares)		28,802
Ending balance at Sep. 30, 2022		$ 1,685,514	$ 367	$ (195,447)	997,115	798,372	85,107
Ending balance, Common stock (in shares) at Sep. 30, 2022		36,733,790	36,733,790
Ending balance, Treasury stock (in shares) at Sep. 30, 2022		6,146,055		6,146,055
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income attributable to noncontrolling interest-redeemable		$ 6,991
Beginning balance at Mar. 31, 2022		1,647,807	$ 367	$ (193,470)	984,784	770,479	85,647
Beginning balance, Common stock (in shares) at Mar. 31, 2022			36,687,528
Beginning balance, Treasury stock (in shares) at Mar. 31, 2022				6,128,754
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	[2]	12,708				10,584	2,124
Acquired noncontrolling interest		707					707
Noncontrolling interest distributions		(3,281)					(3,281)
Nonvested stock compensation		4,943			4,943
Issuance of vested stock (in shares)			7,556
Treasury shares redeemed to pay income tax		(508)		$ (852)	344
Treasury shares redeemed to pay income tax (in shares)				5,144
Exercise of options (in shares)			5,124	2,319
Exercise of options		(218)		$ (68)	(150)
Purchase of additional controlling interest		$ (376)			(209)		(167)
Issuance of common stock under Employee Stock Purchase Plan (in shares)		3,342	3,342
Issuance of common stock under Employee Stock Purchase Plan		$ 535			535
Ending balance at Jun. 30, 2022		1,662,317	$ 367	$ (194,390)	990,247	781,063	85,030
Ending balance, Common stock (in shares) at Jun. 30, 2022			36,703,550
Ending balance, Treasury stock (in shares) at Jun. 30, 2022				6,136,217
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	[2]	20,020				17,309	2,711
Noncontrolling interest distributions		(2,581)					(2,581)
Nonvested stock compensation		5,971			5,971
Issuance of vested stock (in shares)			17,274
Treasury shares redeemed to pay income tax		(415)		$ (927)	512
Treasury shares redeemed to pay income tax (in shares)				5,908
Exercise of options (in shares)			8,862	3,930
Exercise of options		(348)		$ (130)	(218)
Purchase of additional controlling interest		$ (57)			(4)		(53)
Issuance of common stock under Employee Stock Purchase Plan (in shares)		4,104	4,104
Issuance of common stock under Employee Stock Purchase Plan		$ 607			607
Ending balance at Sep. 30, 2022		$ 1,685,514	$ 367	$ (195,447)	$ 997,115	$ 798,372	$ 85,107
Ending balance, Common stock (in shares) at Sep. 30, 2022		36,733,790	36,733,790
Ending balance, Treasury stock (in shares) at Sep. 30, 2022		6,146,055		6,146,055
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income attributable to noncontrolling interest-redeemable		$ 2,000

[1]Net income excludes net income attributable to noncontrolling interest-redeemable of $2.9 million and $9.1 million during the three and nine months ended September 30, 2021. Noncontrolling interest-redeemable is reflected outside of permanent equity on the condensed consolidated balance sheets. See Note 8 of the Notes to Condensed Consolidated Financial Statements.[2]Net income excludes net income attributable to noncontrolling interest-redeemable of $2.0 million and $7.0 million during the three and nine months ended September 30, 2022. Noncontrolling interest-redeemable is reflected outside of permanent equity on the condensed consolidated balance sheets. See Note 8 of the Notes to Condensed Consolidated Financial Statements.

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Operating activities:
Net income	$ 61,933	$ 122,046
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization expense	17,483	14,899
Amortization of operating lease right of use asset	30,769	27,526
Stock-based compensation expense	15,290	11,717
Deferred income taxes	17,635	23,356
Loss (gain) on disposal of assets	484	(1,190)
Impairment of intangibles and other	4,130	937
Changes in operating assets and liabilities, net of acquisitions:
Receivables	(684)	(27,038)
Prepaid expenses	5,273	397
Other assets	(4,208)	(6,368)
Prepaid income taxes	(11,772)	(11,575)
Prepaid taxes	0	(12,509)
Accounts payable and accrued expenses	16,282	6,626
Salaries, wages, and benefits payable	(11,251)	(9,687)
Contract liabilities - deferred revenue	(101,649)	(141,629)
Operating lease liabilities	(30,568)	(27,472)
Income taxes payable	668	(20,819)
Net amounts due to/from governmental entities	223	(833)
Net cash provided by (used in) operating activities	10,038	(51,616)
Investing activities:
Purchases of property, building and equipment	(14,074)	(23,548)
Proceeds from sale of property, building and equipment	0	3,350
Cash paid for acquisitions, net of cash acquired	(2,570)	(383,475)
Purchase of intangible assets	(100)	0
Proceeds from sale of an entity	0	1,531
Minority interest investments	(15,250)	(10,100)
Net cash used in investing activities	(31,994)	(412,242)
Financing activities:
Proceeds from line of credit	815,155	544,056
Payments on line of credit	(738,352)	(209,056)
Government stimulus advance	0	(93,257)
Proceeds from employee stock purchase plan	1,840	1,877
Payments on deferred financing fees	0	(2,855)
Payments on repurchasing common stock	(34,565)	0
Noncontrolling interest distributions	(16,346)	(22,187)
Withholding taxes paid on stock-based compensation	(4,630)	(11,594)
Purchase of additional controlling interest	(433)	(2,113)
Sale of noncontrolling interest	0	1,934
Net cash provided by financing activities	22,669	206,805
Change in cash	713	(257,053)
Cash at beginning of period	9,809	286,569
Cash at end of period	10,522	29,516
Supplemental disclosures of cash flow information:
Interest paid	18,049	1,532
Income taxes paid	10,701	42,036
Non-Cash Operating Activity:
Operating right of use assets in exchange for lease obligations	28,435	41,776
Reduction to right of use assets and liabilities	2,089	2,746
Non-Cash Investing Activity:
Net working capital adjustment	1,440	0
Accrued capital expenditures	$ 126	$ 1,807

Basis of Presentation and Signi

Basis of Presentation and Significant Events	9 Months Ended
Basis of Presentation and Significant Events	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation and Significant Events	Basis of Presentation and Significant Events Organization LHC Group, Inc. (the “Company”) is a health care provider specializing in the post-acute continuum of care. The Company provides services through five segments: home health, hospice, home and community-based services, facility-based services, the latter primarily through long-term acute care hospitals (“LTACHs”), and healthcare innovations services ("HCI"). As of September 30, 2022 , the Company, through its wholly- and majority-owned subsidiaries, equity joint ventures, controlled affiliates, and management agreements operated 942 service locations in 37 states within the continental United States and the District of Columbia. LHC Group, Inc. and UnitedHealth Group Incorporated Merger On March 28, 2022, the Company entered into an Agreement and Plan of Merger (the "Merger Agreement") with UnitedHealth Group Incorporated ("Parent") and Lightning Merger Sub Inc., a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub will be merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent. At a Special Meeting of Stockholders held on June 21, 2022, the stockholders of the Company approved the Merger. The parties to the Merger continue to work toward the expected consummation of the Merger prior to the end of 2022; however, such consummation remains subject to the satisfaction of the remaining closing conditions, including the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. COVID-19 Update SARS-CoV-2 ("COVID-19") continues to cause disruption in the economy, in terms of increased costs and disruptions in the labor market. The impact of COVID-19 is lessened as vaccines have become available in the United States; however, we continue to see periodic increases in the number of cases due to the spread of COVID-19 variants. The effects of COVID-19 continue to materially impact our business. As a result, operating results for the three and nine months ended September 30, 2022 may not be indicative of the results that may be expected for the year ending December 31, 2022, and operating results for the three and nine months ended September 30, 2022 may not be directly comparable to operating results for the three and nine months ended September 30, 2021. CARES Act In response to COVID-19, the U.S. Government enacted the Coronavirus Aid, Relief, and Economic Security Act ("CARES Act") on March 27, 2020. The CARES Act also provided financial hardship relief to Medicare providers impacted by the COVID-19 pandemic in order to provide necessary funds when there is a disruption in Medicare claims submission and/or Medicare claims processing by distributing funds through the Accelerated and Advanced Payments Program ("CAAP"). In addition, the CARES Act suspended the 2% sequestration payment adjustments on Medicare patient claims with dates of service from May 1 through December 31, 2020, suspended the application of site-neutral payment for LTACH admissions that were admitted during the Public Health Emergency ("PHE"), and delayed payment of the employer portion of social security tax. On April 14, 2021, Congress passed legislation to continue the suspension of the 2% sequestration payment adjustments on Medicare patient claims with dates of service through December 31, 2021. On December 10, 2021, the Protecting Medicare and American Farmers from Sequester Cut Act legislation passed, which continued the suspension of the sequestration payment adjustments for Medicare patient claims with dates of service through March 31, 2022. Medicare patient claims with dates of service between April 1 through June 30, 2022 had a 1% sequestration adjustment and Medicare patient claims with dates of service that began on July 1, 2022 had a 2% sequestration adjustment. On October 13, 2022, the U.S. Department of Health and Human Services extended the PHE until January 11, 2023. CAAP As of December 31, 2021, the Company had $106.5 million of accelerated payments under the CAAP, which was recorded in contract liabilities - deferred revenue i n our condensed consolidated balance sheets in accordance with Accounting Standards Update ("ASU") 2014-09, Revenue from Contracts with Customers ("Topic 606") . On October 1, 2020, the repayment and recoupment terms for CAAP funds were amended by the Continuing Appropriations Act, 2021 and Other Extensions Act, which provides that recoupment will begin one year from the date the CAAP funds were received. Under these revised terms, recoupment of CAAP will occur under a tiered approach. The repayment terms began one year starting from the date the CAAP funds were issued and continued for 11 months, with CMS recouping the initial 25% of Medicare payments otherwise owed to the Company. If any amount of CAAP funds that we received from CMS remains unpaid after the initial 11 month period, CMS recoups 50% of Medicare payments otherwise owed to the Company during the following six months. Interest will begin accruing on any amount of the CAAP funds that we received from CMS that remain unpaid following those recoupment periods. CMS will issue a repayment letter to the Company for any such outstanding amounts, which must be paid in full within 30 days from the date of the letter. The Company intends to repay the full amount before any interest accrues. During the nine months ended September 30, 2022, $101.6 million was recouped by CMS and $4.8 million of contract liabilities - deferred revenue remains on our condensed consolidated balance sheets as of September 30, 2022. Other The Company recognized the following amounts of net service revenue due to the suspension of the 2% sequestration payment adjustment and suspension of LTACH site-neutral payments (amounts in thousands): Three months ended September 30, Nine months ended September 30, 2022 2021 2022 2021 Suspension of 2% sequestration payment adjustment $ — $ 6,811 $ 9,952 $ 19,665 Suspension of LTACH site-neutral payment 4,918 5,749 17,070 18,230 As of September 30, 2022, the Company deferred $26.8 million of employer social security taxes, which was recorded in current liabilities - deferred employer payroll tax on our condensed consolidated balance sheets. Unaudited Interim Financial Information The accompanying unaudited condensed consolidated balance sheets as of September 30, 2022 and December 31, 2021, the related unaudited condensed consolidated statements of income for the three and nine months ended September 30, 2022 and 2021, the unaudited condensed consolidated statements of stockholders' equity for the three and nine months ended September 30, 2022 and 2021, the unaudited condensed consolidated statements of cash flows for the nine months ended September 30, 2022 and 2021, and related notes (collectively, these financial statements are referred to as the "interim financial statements" and together with the related notes are referred to herein as the “interim financial information”) have been prepared by the Company. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) have been included. Operating results for the three and nine months ended September 30, 2022 are not necessarily indicative of the results that may be expected for the year ending December 31, 2022. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from the interim financial information presented. This report should be read in conjunction with the Company’s consolidated financial statements and related notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021 (the "2021 Form 10-K"), which was filed with the Securities and Exchange Commission (the “SEC”) on February 24, 2022, as amended by Amendment No. 1 filed on Form 10-K/A filed by the Company on April 27, 2022 (the "Form 10-K Amendment"). The 2021 Form 10-K and Form 10-K Amendment include information and disclosures not included herein.

Significant Accounting Policies

Significant Accounting Policies	9 Months Ended
Significant Accounting Policies	Sep. 30, 2022
Accounting Policies [Abstract]
Significant Accounting Policies	Significant Accounting Policies Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported revenue and expenses during the reporting period. Actual results could differ from those estimates. Net Service Revenue Net service revenue from contracts with customers is recognized in the period the performance obligations are satisfied under the Company's contracts by transferring the requested services to patients in amounts that reflect the consideration to which is expected to be received in exchange for providing patient care, which is the transaction price allocated to the services provided in accordance with Topic 606 and ASU 2015-14 , Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date (collectively, "ASC 606"). Net service revenue is recognized as performance obligations are satisfied, which can vary depending on the type of services provided. The performance obligation is the delivery of patient care in accordance with the requested services outlined in physicians' orders, which are based on specific goals for each patient. The performance obligations are associated with contracts in duration of less than one year; therefore, the optional exemption provided by ASC 606 was elected resulting in the Company not being required to disclose the aggregate amount of the transaction price allocated to the performance obligations that are unsatisfied or partially unsatisfied as of the end of the reporting period. The Company's unsatisfied or partially unsatisfied performance obligations are primarily completed when the patients are discharged and typically occur within days or weeks of the end of the period. The Company determines the transaction price based on gross charges for services provided, reduced by estimates for explicit and implicit price concessions. Explicit price concessions include contractual adjustments provided to patients and third-party payors. Implicit price concessions include discounts provided to self-pay, uninsured patients or other payors, adjustments resulting from regulatory reviews, audits, billing reviews and other matters. Subsequent changes to the estimate of the transaction price are recorded as adjustments to net service revenue in the period of change. Subsequent changes that are determined to be the result of an adverse change in the patient's ability to pay (i.e., change in credit risk) are recorded as a provision for doubtful accounts within general and administrative expenses. Explicit price concessions are recorded for the difference between our standard rates and the contracted rates to be realized from patients, third-party payors and others for services provided. Implicit price concessions are recorded for self-pay, uninsured patients and other payors by major payor class based on historical collection experience and current economic conditions, representing the difference between amounts billed and amounts expected to be collected. The Company assesses the ability to collect for the healthcare services provided at the time of patient admission based on the verification of the patient's insurance coverage under Medicare, Medicaid, and other commercial or managed care insurance programs. Amounts due from third-party payors, primarily commercial health insurers and government programs (Medicare and Medicaid), include variable consideration for retroactive revenue adjustments due to settlements of audits and reviews. The Company has determined estimates for price concessions related to regulatory reviews based on historical experience and success rates in the claim appeals and adjudication process. Revenue is recorded at amounts estimated to be realizable for services provided. The following table sets forth the percentage of net service revenue earned by category of payor for the three and nine months ended September 30, 2022 and 2021: Three months ended Nine months ended 2022 2021 2022 2021 Home health: Medicare 59.7 % 62.1 % 59.4 % 62.8 % Managed Care, Commercial, and Other 40.3 37.9 40.6 37.2 100.0 % 100.0 % 100.0 % 100.0 % Hospice: Medicare 92.7 % 94.6 % 92.8 % 94.3 % Managed Care, Commercial, and Other 7.3 5.4 7.2 5.7 100.0 % 100.0 % 100.0 % 100.0 % Home and community-based services: Medicaid 38.3 % 32.1 % 36.8 % 31.1 % Managed Care, Commercial, and Other 61.7 67.9 63.2 68.9 100.0 % 100.0 % 100.0 % 100.0 % Facility-based services: Medicare 53.0 % 45.8 % 53.0 % 49.5 % Managed Care, Commercial, and Other 47.0 54.2 47.0 50.5 100.0 % 100.0 % 100.0 % 100.0 % HCI: Medicare 2.8 % 6.0 % 5.4 % 11.4 % Managed Care, Commercial, and Other 97.2 94.0 94.6 88.6 100.0 % 100.0 % 100.0 % 100.0 % Medicare The following describes the payment models in effect during the nine months ended September 30, 2022. Such payment models were subject to temporary adjustments made by CMS in response to COVID-19 pandemic as described elsewhere in this Quarterly Report on Form 10-Q. The 2% sequestration reduction adjustment was suspended for patient claims with dates of service through March 31, 2022. Medicare patient claims with dates of service between April 1 through June 30, 2022 had a 1% sequestration payment adjustment. Medicare patient claims with dates of service beginning July 1, 2022 had the full 2% sequestration payment adjustment. Home Health Services The Company records revenue as services are provided under the Patient Driven Groupings Model ("PDGM"). For each 30-day period, the patient is classified into one of 432 home health resource groups prior to receiving services. Each 30-day period is placed into a subgroup falling under the following categories: (i) timing being early or late, (ii) admission source being community or institutional, (iii) one of 12 clinical groupings based on the patient's principal diagnosis, (iv) functional impairment level of low, medium, or high, and (v) a co-morbidity adjustment of none, low, or high based on the patient's secondary diagnoses. Each 30-day period payment from Medicare reflects base payment adjustments for case-mix and geographic wage differences. In addition, payments may reflect one of three retroactive adjustments to the total reimbursement: (a) an outlier payment if the patient’s care was unusually costly; (b) a low utilization adjustment whereby the number of visits is dependent on the clinical grouping; and/or (c) a partial payment if the patient transferred to another provider or from another provider before completing the episode. The retroactive adjustments outlined above are recognized in net service revenue when the event causing the adjustment occurs and during the period in which the services are provided to the patient. The Company reviews these adjustments to ensure that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the retroactive adjustments is subsequently resolved. Net service revenue and related patient accounts receivable are recorded at amounts estimated to be realized from Medicare for services rendered. Hospice The Company records revenue based upon the date of service at amounts equal to the estimated payment rates. The Company receives one of four predetermined daily rates based upon the level of care provided by the Company, which can be routine care, general inpatient care, continuous home care, and respite care. There are two separate payment rates for routine care: payment for the first 60 days of care and care beyond 60 days. In addition to the two routine rates, the Company may also receive a service intensity add-on ("SIA"). The SIA is based on visits made in the last seven days of life by a registered nurse or medical social worker for patients in a routine level of care. The performance obligation is the delivery of hospice services to the patient, as determined by a physician, each day the patient is on hospice care. Adjustments to Medicare revenue are made from regulatory reviews, audits, billing reviews and other matters. The Company estimates the impact of these adjustments based on our historical experience. Hospice payments are subject to variable consideration through an inpatient cap and an overall Medicare payment cap. The inpatient cap relates to individual programs receiving more than 20% of their total Medicare reimbursement from inpatient care services, and the overall Medicare payment cap relates to individual programs receiving reimbursements in excess of a “cap amount,” determined by Medicare to be payment equal to 12 months of hospice care for the aggregate base of hospice patients, indexed for inflation. The determination for each cap is made annually based on the 12-month period ending on September 30 of each year. The Company monitors its limits on a provider-by-provider basis and records an estimate of its liability for reimbursements received in excess of the cap amount, if any, in the reporting period. Facility-Based Services Gross revenue is recorded as services are provided under the LTACH prospective payment system. Each patient is assigned a long-term care diagnosis-related group. The Company is paid a predetermined fixed amount intended to reflect the average cost of treating a Medicare LTACH patient classified in that particular long-term care diagnosis-related group. For selected LTACH patients, the amount may be further adjusted based on length-of-stay and facility-specific costs, as well as in instances where a patient is discharged and subsequently re-admitted, among other factors. The Company calculates the adjustment based on a historical average of these types of adjustments for LTACH claims paid. Similar to other Medicare prospective payment systems, the rate is also adjusted for geographic wage differences. Net service revenue adjustments resulting from reviews and audits of Medicare cost report settlements are considered implicit price concessions for LTACHs and are measured at expected value. Non-Medicare Revenues Other sources of net service revenue for all segments fall into Medicaid, managed care or other payors of the Company's services. Medicaid reimbursement is based on a predetermined fee schedule applied to each service provided. Therefore, revenue is recognized for Medicaid services as services are provided based on this fee schedule. The Company's managed care and other payors reimburse the Company based upon a predetermined fee schedule or an episodic basis, depending on the terms of the applicable contract. Accordingly, the Company recognizes revenue from managed care and other payors as services are provided, such costs are incurred, and estimates of expected payments are known for each different payor, thus the Company's revenue is recorded at the estimated transaction price. Contingent Service Revenues The HCI segment provides strategic health management services to Accountable Care Organizations ("ACOs") that have been approved to participate in the Medicare Shared Savings Program ("MSSP"). The HCI segment has service agreements with ACOs that provide for sharing of MSSP payments received by the ACO, if any. ACOs are legal entities that contract with CMS to provide services to the Medicare fee-for-service population for a specified annual period with the goal of providing better care for the individual, improving health for populations and lowering costs. ACOs share savings with CMS to the extent that the actual costs of serving assigned beneficiaries are below certain trended benchmarks of such beneficiaries and certain quality performance measures are achieved. The generation of shared savings is the performance obligation of each ACO, which only become certain upon the final issuance of unembargoed calculations by CMS, generally in the third quarter of each year. During the nine months ended September 30, 2022 and 2021, the Company recorded in its HCI segment $15.6 million and $12.1 million, respectively, related to 2021 and 2020 ACO respective service periods, as certain ACOs served by the HCI segment received a MSSP payment from CMS confirming the performance obligation has been met. Patient Accounts Receivable The Company reports patient accounts receivable from services rendered at their estimated transaction price, which includes price concessions based on the amounts expected from payors. The Company's patient accounts receivable is uncollateralized and primarily consist of amounts due from Medicare, Medicaid, other third-party payors, and to a lesser degree patients. The credit risk from other payors is limited due to the significance of Medicare as the primary payor. The Company believes the credit risk associated with its Medicare accounts is limited due to (i) the historical collection rate from Medicare and (ii) the fact that Medicare is a U.S. government payor. The Company does not believe that there are any other significant concentrations from any particular payor that would subject it to any significant credit risk in the collection of patient accounts receivable. Earnings Per Share Basic per share information is computed by dividing the relevant amounts from the condensed consolidated statements of income by the weighted-average number of shares outstanding during the period, under the treasury stock method. Diluted per share information is also computed using the treasury stock method, by dividing the relevant amounts from the condensed consolidated statements of income by the weighted-average number of shares outstanding plus potentially dilutive shares. The following table sets forth shares used in the computation of basic and diluted per share information and, with respect to the data provided for the three and nine months ended September 30, 2022 and 2021 (amounts in thousands): Three months ended Nine months ended 2022 2021 2022 2021 Weighted average number of shares outstanding for basic per share calculation 30,565 31,238 30,527 31,205 Effect of dilutive potential shares: Nonvested stock 141 196 112 217 Adjusted weighted average shares for diluted per share calculation 30,706 31,434 30,639 31,422 Anti-dilutive shares 87 6 264 118 Investments

Acquisitions

Acquisitions	9 Months Ended
Acquisitions	Sep. 30, 2022
Business Combination and Asset Acquisition [Abstract]
Acquisitions	Acquisitions On September 1, 2021, the Company purchased Heart of Hospice. During the nine months ended September 30, 2022, the Company recorded a decrease in patient accounts receivable of $1.5 million due to information obtained that related to facts and circumstances that existed at the time of acquisition; therefore, it was an adjustment to the provisional amounts previously recognized. On November 1, 2021, the Company purchased Brookdale Health Care Services' agencies from the recently formed home health, hospice, and outpatient therapy venture between HCA Healthcare and Brookdale Senior Living. The Company's net working capital adjustment was finalized during the nine months ended September 30, 2022 for $3.1 million and recorded in accordance with ASC Topic 805, Business Combinations, as an increase to the consideration transferred. In addition, amounts due to government entities was reduced by $3.2 million to reflect payments made for prior years' hospice cap liability. On May 1, 2022, the Company purchased the majority ownership of a home health agency from Archbold Medical Center, which included two locations in Georgia. Total consideration for the acquisition was $3.7 million. The purchase price was determined based on the Company's analysis of comparable acquisitions and the target market's potential future cash flows. Goodwill generated from the acquisitions was recognized based on the expected contributions of each acquisition to the overall corporate strategy. The Company expects its portion of goodwill to be fully tax deductible. The acquisitions were accounted for under the acquisition method of accounting. Accordingly, the accompanying financial information includes the results of operations of the acquired entities from the date of acquisition. The following table summarizes the preliminary amounts of the assets acquired and liabilities assumed at their acquisition date, as well as their fair value at the acquisition date and the noncontrolling interest acquired during the nine months ended September 30, 2022 (amounts in thousands): Consideration Cash $ 2,570 Fair value of total consideration transferred Recognized amounts of identifiable assets acquired and liabilities assumed: Trade name $ 453 Certificates of need/licenses 357 Other liabilities (227) Total identifiable assets and liabilities $ 583 Noncontrolling interest $ 707 Goodwill, including noncontrolling interest of $504 $ 2,694 Trade names and certificates of need/licenses are indefinite-lived assets and, therefore, not subject to amortization. Acquired trade names that are not being used actively are amortized over the estimated useful life on the straight line basis. Trade names are valued using the relief from royalty method, a form of the income approach. Certificates of need are valued using the replacement cost approach based on registration fees and opportunity costs. Licenses are valued based on the estimated direct costs associated with recreating the asset, including opportunity costs based on an income approach. In the case of states with a moratorium in place, the licenses are valued using the multi-period excess earnings method. Noncontrolling interest is recorded at fair value.

Goodwill and Intangibles

Goodwill and Intangibles	9 Months Ended
Goodwill and Intangibles	Sep. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangibles	Goodwill and Intangibles The changes in recorded goodwill and intangible assets by reporting unit for the nine months ended September 30, 2022 were as follows (amounts in thousands): Home health reporting unit Hospice Home and community-based services Facility-based HCI reporting unit Total Goodwill: Balance as of December 31, 2021 $ 968,435 $ 556,332 $ 167,027 $ 15,770 $ 40,862 $ 1,748,426 Net working capital adjustments — 1,440 — — — 1,440 Acquisitions 2,190 — — — — 2,190 Noncontrolling interests 504 — — — — 504 Disposals (440) (1,460) (240) — — (2,140) Balance as of September 30, 2022 $ 970,689 $ 556,312 $ 166,787 $ 15,770 $ 40,862 $ 1,750,420 Intangible assets: Balance as of December 31, 2021 $ 237,979 $ 117,340 $ 24,245 $ 5,919 $ 14,519 $ 400,002 Acquisitions 1,010 — — — — 1,010 Amortization (1,589) (1,346) (8) (334) (436) (3,713) Disposals (491) (1,217) (282) — — (1,990) Balance as of September 30, 2022 $ 236,909 $ 114,777 $ 23,955 $ 5,585 $ 14,083 $ 395,309 The Company did record impairments of goodwill and intangible assets related to the closure of underperforming locations. Goodwill impairment of $2.1 million and Medicare licenses/Certificate of need impairment of $2.0 million were recorded during the nine months ended September 30, 2022. Goodwill impairment of $0.02 million and Medicare licenses impairment of $0.9 million were recorded during the nine months ended September 30, 2021. This was recorded in impairment of intangibles and other on the Company's condensed consolidated statements of income. The amount of disposal of goodwill was determined using prices of comparable businesses in the market. The amount of disposal of the Medicare licenses/Certificate of need was its carrying value at the time of closure. The following tables summarize the changes in intangible assets during the nine months ended September 30, 2022 and December 31, 2021 (amounts in thousands): 2022 2021 Indefinite-lived intangible assets: Trade names $ 208,160 $ 207,780 Certificates of need/licenses 172,395 173,955 Net total $ 380,555 $ 381,735 Definite-lived intangible assets: Trade names Gross carrying amount $ 11,273 $ 11,073 Accumulated amortization (10,559) (9,606) Net total $ 714 $ 1,467 Non-compete agreements Gross carrying amount $ 14,524 $ 14,524 Accumulated amortization (9,495) (7,172) Net total $ 5,029 $ 7,352 Customer relationships Gross carrying amount $ 11,822 $ 11,822 Accumulated amortization (2,811) (2,374) Net total $ 9,011 $ 9,448 Total definite-lived intangible assets Gross carrying amount $ 37,619 $ 37,419 Accumulated amortization (22,865) (19,152) Net total $ 14,754 $ 18,267 Total intangible assets: Gross carrying amount $ 418,174 $ 419,154 Accumulated amortization (22,865) (19,152) Net total $ 395,309 $ 400,002 Remaining useful lives for trade names, customer relationships, and non-compete agreements wer e 7.0, 15.5, and 4.2 years, respectively, at September 30, 2022. Similar periods at December 31, 2021 were 7.8, 16.3, and 4.9 years for trade names, customer relationships, and non-compete agreements, respectively. Amortization expense was $1.0 million and $0.4 million for the three months ended September 30, 2022 and 2021 and $3.7 million and $1.0 million for the nine months ended September 30, 2022 and 2021. Amortization expense was recorded in general and administrative expenses.

Debt

Debt	9 Months Ended
Debt	Sep. 30, 2022
Debt Disclosure [Abstract]
Debt	Debt Credit Facility On August 3, 2021, the Company entered into an Amended and Restated Senior Credit Facility (the "2021 Amended Credit Agreement"), which provided a senior, secured revolving line of credit commitment with a maximum principal borrowing limit of $800.0 million, which included an additional $500.0 million accordion expansion, and a letter of credit sub-limit equal to $75.0 million. On December 31, 2021, the aggregate commitment was increased to a maximum borrowing limit of $1.0 billion, with an additional $300.0 million accordion expansion. The expiration date of the 2021 Amended Credit Agreement is August 3, 2026. The Company’s obligations under the 2021 Amended Credit Agreement are secured by substantially all of the assets of the Company and its wholly-owned subsidiaries (subject to customary exclusions), which assets include the Company’s equity ownership of its wholly-owned subsidiaries and its equity ownership in joint venture entities. The Company’s wholly-owned subsidiaries also guarantee the obligations of the Company under the 2021 Amended Credit Agreement. Revolving loans under the 2021 Amended Credit Agreement bear interest, as selected by the Company, at either (i) the prevailing London Interbank Offered Rate ("LIBOR") (with interest periods of one, three or six months at the Company's option) plus a spread of 1.25% to 2.0% based on the Company's quarterly consolidated Leverage Ratio or (ii) the prevailing prime or base rate plus a spread of 0.25% to 1.00% based on the Company's quarterly consolidated Leverage Ratio. Swing line loans bear interest at the Base Rate. The Company is limited to 15 Eurodollar borrowings outstanding at any time. The Company is required to pay a commitment fee for the unused commitments at rates ranging from 0.15% to 0.30% per annum depending upon the Company’s quarterly consolidated Leverage Ratio. The Base Rate as of September 30, 2022 was 7.25% and the LIBOR rate was 5.13%. As of September 30, 2022, the effective interest rate on outstanding borrowings under the 2021 Amended Credit Agreement was 4.98%. On March 5, 2021, the ICE Benchmark Administration, the administrator of LIBOR, announced its intention to cease the publication of LIBOR settings for 1-month, 3-month, 6-month, and 12-month LIBOR borrowings immediately on June 30, 2023. JPMorgan Chase Bank, N.A will transition our 2021 Amended Credit Agreement to an alternate rate to CME Term SOFR Reference Rate ("SOFR"), which is administered by CME Group Benchmark Administration Ltd ("CME"). Due to the differences observed between LIBOR rates and SOFR published rates, JPMorgan Chase Bank, N.A. will use a credit spread adjustment ("CSA") in order to minimize value transfer and leave the existing margin applicable to our 2021 Amended Credit Agreement. The CSA used by JPMorgan Chase Bank, N.A. is based on the average of the differences between LIBOR and SOFR over a 12-month period and will be added to SOFR. As of September 30, 2022, the Company had $738.0 million drawn, letters of credit issued in the amount of $24.3 million, and $237.7 million of remaining borrowing capacity available under the 2021 Amended Credit Agreement. At December 31, 2021, the Company had $661.2 million drawn and letters of credit issued in the amount of $24.3 million under the 2021 Amended Credit Agreement.

Stockholder's Equity

Stockholder's Equity	9 Months Ended
Stockholder's Equity	Sep. 30, 2022
Equity [Abstract]
Stockholder's Equity	Stockholder’s Equity Equity Based Awards The 2018 Incentive Plan is administered by the Compensation Committee of the Company’s Board of Directors. The total number of shares of the Company's common stock originally reserved were 2,210,544 shares and a total of 1,544,734 s hares are currently available for issuance. A variety of discretionary awards for employees, officers, directors, and consultants are authorized under the 2018 Incentive Plan, including incentive or non-qualified stock options and restricted stock, restricted stock units and performance-based awards. All awards must be evidenced by a written award certificate which will include the provisions specified by the Compensation Committee of the Board of Directors. The Compensation Committee determines the exercise price for stock options, which cannot be less than the fair market value of the Company’s common stock as of the date of grant. Share Based Compensation Nonvested Stock Independent directors are granted shares of common stock under the Second Amended and Restated 2005 Non-Employee Directors Compensation Plan. During the nine months ended September 30, 2022, the Com pany granted 8,800 nonvested shares of common stock to independent directors, which shares will vest 100% on the one year anniversary date. During the nine months ended September 30, 2022, employees and a consultant were granted 182,310 and 10,935 shares, respectively, of nonvested shares of common stock pursuant to the 2018 Incentive Plan. The shares vest over a p eriod of five years, conditioned on continued employment and in accordance with the consulting agreement. The fair value of nonvested shares of common stock is determined based on the closing trading price of the Company’s common stock on the grant date. The following table represents the share grants activity for the nine months ended September 30, 2022: Restricted stock Options Number of shares Weighted Number of shares Weighted Share grants outstanding as of December 31, 2021 415,816 $ 122.40 74,235 $ 42.07 Granted 202,045 139.64 — — Vested or exercised (162,749) 143.35 (13,986) 31.27 Share grants outstanding as of September 30, 2022 455,112 $ 134.44 60,249 $ 43.05 As of September 30, 2022, there was $49.6 million of total unrecognized compensation cost related to nonvested shares of common stock granted. That cost is expected to be recognized over the weighted average period of 3.25 years. The Company records compensation expense related to nonvested stock awards at the grant date for shares of common stock that are awarded fully vested, and over the vesting term on a straight-line basis for shares of common stock that vest over time. The Company estimates forfeitures at the time of grant and revises the estimate in subsequent periods if actual forfeitures differ to ensure that total compensation expense recognized is at least equal to the value of vested awards. The Company record ed $15.3 million and $11.7 million of compensation expense related to nonvested stock grants for the nine months ended September 30, 2022 and 2021, respectively. Employee Stock Purchase Plan In 2006, the Company adopted the Employee Stock Purchase Plan whereby eligible employees may purchase the Company’s common stock at 95% of the market price on the last day of the calendar quarter. There were 250,000 shares of common stock initially reserved for the plan. In 2013, the Company adopted the Amended and Restated Employee Stock Purchase Plan, which reserved an additional 250,000 shares of common stock to the plan. The table below details the shares of common stock issued during 2022: Number of Per share Shares available as of December 31, 2021 104,344 Shares issued during the three months ended March 31, 2022 5,353 $ 130.37 Shares issued during the three months ended June 30, 2022 3,342 $ 160.17 Shares issued during the three months ended September 30, 2022 4,104 $ 147.95 Shares available as of September 30, 2022 91,545 Treasury Stock In conjunction with the vesting of the nonvested shares of common stock or the exercise of stock options, recipients incur perso nal income tax obligations. The Company allows the recipients to turn in shares of common stock to satisfy minimum tax obligations. During the nine months ended September 30, 2022, the Company redeemed 28,802 shares of common stock valued at $5.0 million, related to share vesting tax obligations. Such shares are held as treasury stock and are available for reissuance by the Company. Additionally, 5,268 share s were forfeited for terminated employees. Such shares are held in treasury stock and are available for reissuance by the Company. In addition, the Company redee med 6,249 shares of common stock valued at $0.2 million, r elated to the exercise of options. Stock Repurchase On December 6, 2021, the Company's Board of Directors approved a share repurchase program authorizing purchases up to $250.0 million of the Company's common stock. The Company may purchase common stock in open market transactions, block or privately negotiated transactions, and may from time to time purchase shares pursuant to a trading plan in accordance with Rule 10b5-1 and Rule 10b-18 under the Exchange Act or by any combination of such methods, in each case subject to compliance with all SEC rules and other legal requirements. The number of shares to be purchased and the timing of the purchases are based on a variety of factors, including, but not limited to, the level of cash balances, credit availability, debt covenant restrictions, general business conditions, the market price of our stock and the availability of alternative investment opportunities. No time limit was set for completion of repurchases under the new authorization, and the program may be suspended or discontinued at any time.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
Commitments and Contingencies	Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Contingencies The Company provides services in a highly regulated industry and is a party to various proceedings and regulatory and other governmental and internal audits and investigations in the ordinary course of business (including audits by Zone Program Integrity Contractors ("ZPICs"), Unified Program Integrity Contractors ("UPICs"), and Recovery Audit Contractors ("RACs") and investigations resulting from the Company's obligation to self-report suspected violations of law). Management cannot predict the ultimate outcome of any regulatory and other governmental and internal audits and investigations. While such audits and investigations are the subject of administrative appeals, the appeals process, even if successful, may take several years to resolve. The Department of Justice, CMS, or other federal and state enforcement and regulatory agencies may conduct additional investigations related to the Company's businesses. These audits and investigations have caused and could potentially continue to cause delays in collections, recoupments from governmental payors. The Company recorded $12.0 million and $16.9 million in its condensed consolidated balance sheets in other assets as of September 30, 2022 and December 31, 2021, respectively, which are due from government payors related to the disputed finding of pending appeals of ZPIC audits. Additionally, these audits may subject the Company to sanctions, damages, extrapolation of damage findings, additional recoupments, fines, and other penalties (some of which may not be covered by insurance), which may, either individually or in the aggregate, have a material adverse effect on the Company's business and financial condition. We are involved in various legal proceedings arising in the ordinary course of business. Although the results of litigation cannot be predicted with certainty, we believe the outcome of pending litigation will not have a material adverse effect, after considering the effect of our insurance coverage, on our consolidated financial information. Legal fees related to all legal matters are expensed as incurred. Joint Venture Buy/Sell Provisions Most of the Company’s joint ventures include a buy/sell option that grants to the Company and its joint venture partners the right to require the other joint venture party to either purchase all of the exercising member’s membership interests or sell to the exercising member all of the non-exercising member’s membership interest, at the non-exercising member’s option, within 30 days of the receipt of notice of the exercise of the buy/sell option. In some instances, the purchase price is based on a multiple of the historical or future earnings before income taxes and depreciation and amortization of the equity joint venture at the time the buy/sell option is exercised. In other instances, the buy/sell purchase price will be negotiated by the partners and subject to a fair market valuation process. The Company has not received notice from any joint venture partners of their intent to exercise the terms of the buy/sell agreement nor has the Company notified any joint venture partners of its intent to exercise the terms of the buy/sell agreement. Compliance The laws and regulations governing the Company’s operations, along with the terms of participation in various government programs, regulate how the Company does business, the services offered and its interactions with patients and the public. These laws and regulations, and their interpretations, are subject to frequent change. Changes in existing laws or regulations, or their interpretations, or the enactment of new laws or regulations could materially and adversely affect the Company’s operations and financial condition. The Company is subject to various routine and non-routine governmental reviews, audits and investigations. In recent years, federal and state civil and criminal enforcement agencies have heightened and coordinated their oversight efforts related to the health care industry, including referral practices, cost reporting, billing practices, joint ventures and other financial relationships among health care providers. Violation of the laws governing the Company’s operations, or changes in the interpretation of those laws, could result in the imposition of fines, civil or criminal penalties and/or termination of the Company’s rights to participate in federal and state-sponsored programs and suspension or revocation of the Company’s licenses. The Company believes that it is in material compliance with all applicable laws and regulations.

Noncontrolling interests

Noncontrolling interests	9 Months Ended
Noncontrolling interests	Sep. 30, 2022
Noncontrolling Interest [Abstract]
Noncontrolling interests	Noncontrolling interests The Company classifies noncontrolling interests of its joint venture parties based upon a review of the legal provisions governing the redemption of such interests. In each of the Company’s joint ventures, those provisions are embodied within the joint venture’s operating agreement. For joint ventures with operating agreement provisions that establish an obligation for the Company to purchase the third-party partners’ noncontrolling interests other than as a result of events that lead to a liquidation of the joint venture, such noncontrolling interests are classified as redeemable noncontrolling interests in temporary equity. For joint ventures with operating agreement provisions that establish an obligation that the Company purchase the third party partners’ noncontrolling interests, but which obligation is triggered by events that lead to a liquidation of the joint venture, such noncontrolling interests are classified as nonredeemable noncontrolling interests in permanent equity. Additionally, for joint ventures with operating agreement provisions that do not establish an obligation for the Company to purchase the third-party partners’ noncontrolling interests (e.g., where the Company has the option, but not the obligation, to purchase the third-party partners’ noncontrolling interests), such noncontrolling interests are classified as nonredeemable noncontrolling interests in permanent equity. The Company’s equity joint ventures that are classified as redeemable noncontrolling interests are subject to operating agreement provisions that require the Company to purchase the noncontrolling partner’s interest upon the occurrence of certain triggering events, which are defined as the bankruptcy of the partner or the partner’s exclusion from the Medicare or Medicaid programs. These triggering events and the related repurchase provisions are specific to each redeemable equity joint venture, since the triggering of a repurchase obligation for any one redeemable noncontrolling interest in an equity joint venture does not necessarily impact any of the other redeemable noncontrolling interests in other equity joint ventures. Upon the occurrence of a triggering event requiring the purchase of a redeemable noncontrolling interest, the Company would be required to purchase the noncontrolling partner’s interest based upon a valuation methodology set forth in the applicable joint venture agreement. Redeemable noncontrolling interests and nonredeemable noncontrolling interests are initially recorded at their fair value as of the closing date of the transaction establishing the joint venture. Such fair values are determined using various accepted valuation methods, including the income approach, the market approach, the cost approach, and a combination of one or more of these approaches. A number of facts and circumstances concerning the operation of the joint venture are evaluated for each transaction, including (but not limited to) the ability to choose management, control over acquiring or liquidating assets, and controlling the joint venture’s strategy and direction, in order to determine the fair value of the noncontrolling interest. Based upon the Company’s evaluation of the redemption provisions concerning redeemable noncontrolling interests as of September 30, 2022, the Company determined in accordance with authoritative accounting guidance that it was not probable that an event otherwise requiring redemption of any redeemable noncontrolling interest would occur (i.e., the date for such event was not set or such event is not certain to occur). Therefore, none of the redeemable noncontrolling interests were identified as mandatorily redeemable interests at such times, and the Company did not record any values in respect of any mandatorily redeemable interests. Subsequent to the closing date of the transaction establishing the joint venture, the Company records adjustments to the carrying amounts of noncontrolling interests during each reporting period to reflect (a) comprehensive income (loss) attributed to each noncontrolling interest, which is calculated by multiplying the noncontrolling interest percentage by the comprehensive income (loss) of the joint venture’s operations, (b) dividends paid to the noncontrolling interest partner, and (c) any other transactions that increase or decrease the Company’s ownership interest in each joint venture, as a result of which the Company retains its controlling interest. If the Company determines that, based upon its analysis as of the end of each reporting period in accordance with authoritative accounting guidance, that it is not probable that an event would occur to otherwise require the redemption of a redeemable noncontrolling interest (i.e., the date for such event is not set or such event is not certain to occur), then the Company does not adjust the recorded amount of such redeemable noncontrolling interest. The carrying amount of each redeemable equity instrument presented in temporary equity for the nine months ended September 30, 2022 is not less than the initial amount reported for each instrument. The following table summarizes the activity of noncontrolling interest-redeemable for the nine months ended September 30, 2022 (amounts in thousands): Balance as of December 31, 2021 $ 17,501 Net income attributable to noncontrolling interest-redeemable 6,991 Noncontrolling interest-redeemable distributions (7,514) Balance as of September 30, 2022 $ 16,978

Leases

Leases	9 Months Ended
Leases	Sep. 30, 2022
Leases [Abstract]
Leases	LeasesThe Company determines if a contract contains a lease at inception date. The Company's leases are operating leases, primarily for office and office equipment, that expire at various dates over the next five years. The facility-based leases have renewal options for periods ranging from one Payments due under operating leases include fixed and variable payments. These variable payments for the Company's office leases can include operating expenses, utilities, property taxes, insurance, common area maintenance, and other facility-related expense. Additionally, any leases with terms less than one year were not recognized as operating lease right of use assets or payables for short term leases in accordance with the election of ‘package of practical expedient’ under ASU 2016-02. The Company recognizes operating lease right of use assets and operating lease payable based on the present value of the future minimum lease payments at the lease commencement date. The Company's leases do not provide implicit rates. Therefore, the Company used an incremental borrowing rate based on the information available at the lease commencement date in determining the present value of future payments. As of September 30, 2022, the weighted-average remaining lease term was 3.63 years and weighted-average discount rate was 4.11%. The following table summarizes the operating lease right of use assets and related lease payables in our condensed consolidated balance sheets as of September 30, 2022 and December 31, 2021 (amounts in thousands): September 30, 2022 December 31, 2021 Operating lease right of use asset $ 108,975 $ 113,399 Current operating lease liabilities 36,998 37,630 Long-term operating lease liabilities 74,992 78,688 The components of lease costs for operating leases for the three and nine months ended September 30, 2022 and 2021 were as follows (amounts in thousands): Three months ended September 30, Nine months ended September 30, 2022 2021 2022 2021 Operating lease cost $ 14,033 $ 12,791 $ 42,800 $ 37,096 Short-term lease cost 908 927 2,712 2,697 Variable lease cost 1,246 997 3,350 3,058 Total lease costs $ 16,187 $ 14,715 $ 48,862 $ 42,851 Maturities of operating lease liabilities as of September 30, 2022 were as follows (amounts in thousands): Month ending September 30, 2022 $ 11,073 2023 38,472 2024 29,629 2025 21,006 Thereafter 20,224 Total future minimum lease payments 120,404 Less: Imputed interest (8,414) Total $ 111,990

Fair Value of Financial Instrum

Fair Value of Financial Instruments	9 Months Ended
Fair Value of Financial Instruments	Sep. 30, 2022
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	Fair Value of Financial InstrumentsThe carrying amounts of the Company’s cash, receivables, accounts payable and accrued liabilities approximate their fair values because of their short maturity.

Segment Information

Segment Information	9 Months Ended
Segment Information	Sep. 30, 2022
Segment Reporting [Abstract]
Segment Information	Segment InformationThe Company's reporting segments include (1) home health services, (2) hospice services, (3) home and community-based services, (4) facility-based services, and (5) HCI. Reportable segments have been identified based upon how management has organized the business by services provided to customers and how the chief operating decision maker manages the business and allocates resources, consistent with the criteria in ASC 280, Segment Reporting. The following tables summarize the Company’s segment information for the three and nine months ended September 30, 2022 and 2021 (amounts in thousands): Three months ended September 30, 2022 Home health services Hospice services Home and community-based services Facility-based services HCI Total Net service revenue $ 373,335 $ 103,799 $ 47,978 $ 31,441 $ 20,360 $ 576,913 Cost of service revenue (excluding depreciation and amortization) 217,790 68,951 35,727 22,549 2,755 347,772 General and administrative expenses 126,052 32,384 11,893 12,098 6,624 189,051 Impairment of intangibles and other — 1,590 469 — — 2,059 Operating income (loss) 29,493 874 (111) (3,206) 10,981 38,031 Interest expense (6,347) (1,356) (808) (362) (180) (9,053) Income (loss) before income taxes and noncontrolling interest 23,146 (482) (919) (3,568) 10,801 28,978 Income tax expense (benefit) 5,723 (439) (165) (927) 2,774 6,966 Net income (loss) 17,423 (43) (754) (2,641) 8,027 22,012 Less net income (loss) attributable to non controlling interests 3,838 1,269 (125) (439) 160 4,703 Net income (loss) attributable to LHC Group, Inc.'s common stockholder $ 13,585 $ (1,312) $ (629) $ (2,202) $ 7,867 $ 17,309 Total assets $ 1,717,209 $ 798,668 $ 238,082 $ 80,223 $ 79,972 $ 2,914,154 Three months ended September 30, 2021 Home health services Hospice services Home and community-based services Facility-based services HCI Total Net service revenue $ 386,699 $ 82,653 $ 45,800 $ 32,415 $ 17,884 $ 565,451 Cost of service revenue (excluding depreciation and amortization) 230,839 51,631 34,386 23,725 3,281 343,862 General and administrative expenses 126,695 22,548 11,764 11,050 4,387 176,444 Operating income (loss) 29,165 8,474 (350) (2,360) 10,216 45,145 Interest expense (811) (139) (109) (54) (22) (1,135) Income (loss) before income taxes and noncontrolling interest 28,354 8,335 (459) (2,414) 10,194 44,010 Income tax expense (benefit) 6,407 1,874 (99) (554) 2,522 10,150 Net income (loss) 21,947 6,461 (360) (1,860) 7,672 33,860 Less net income (loss) attributable to noncontrolling interests 5,157 1,085 77 (187) (6) 6,126 Net income (loss) attributable to LHC Group, Inc.'s common stockholders $ 16,790 $ 5,376 $ (437) $ (1,673) $ 7,678 $ 27,734 Total assets $ 1,632,670 $ 681,954 $ 239,452 $ 83,276 $ 75,334 $ 2,712,686 Nine months ended September 30, 2022 Home health services Hospice services Home and community-based services Facility-based services HCI Total Net service revenue $ 1,154,009 $ 308,322 $ 137,036 $ 94,289 $ 30,945 $ 1,724,601 Cost of service revenue (excluding depreciation and amortization) 674,508 202,864 96,470 69,584 8,667 1,052,093 General and administrative expenses 387,482 97,152 35,755 35,737 13,674 569,800 Impairment of intangibles and other 930 2,677 523 — — 4,130 Operating income (loss) 91,089 5,629 4,288 (11,032) 8,604 98,578 Interest expense (13,805) (2,803) (1,785) (851) (387) (19,631) Income (loss) before income taxes and noncontrolling interest 77,284 2,826 2,503 (11,883) 8,217 78,947 Income tax expense (benefit) 17,057 (3) 680 (2,849) 2,129 17,014 Net income (loss) 60,227 2,829 1,823 (9,034) 6,088 61,933 Less net income (loss) attributable to non controlling interests 12,758 2,837 (74) (1,085) 150 14,586 Net income (loss) attributable to LHC Group, Inc.'s common stockholder $ 47,469 $ (8) $ 1,897 $ (7,949) $ 5,938 $ 47,347 Nine months ended September 30, 2021 Home health services Hospice services Home and community-based services Facility-based services HCI Total Net service revenue $ 1,157,061 $ 209,191 $ 143,332 $ 96,814 $ 29,795 $ 1,636,193 Cost of service revenue (excluding depreciation and amortization) 663,137 129,848 103,941 65,360 9,720 972,006 General and administrative expenses 369,337 58,789 35,216 33,213 10,199 506,754 Impairment of intangibles and other 937 — — — — 937 Operating income (loss) 123,650 20,554 4,175 (1,759) 9,876 156,496 Interest expense (1,099) (195) (143) (73) (31) (1,541) Income (loss) before income taxes and noncontrolling interest 122,551 20,359 4,032 (1,832) 9,845 154,955 Income tax expense (benefit) 26,003 4,221 889 (649) 2,445 32,909 Net income (loss) 96,548 16,138 3,143 (1,183) 7,400 122,046 Less net income (loss) attributable to non controlling interests 17,506 3,308 441 792 (37) 22,010 Net income (loss) attributable to LHC Group, Inc.'s common stockholder $ 79,042 $ 12,830 $ 2,702 $ (1,975) $ 7,437 $ 100,036

Income Taxes

Income Taxes	9 Months Ended
Income Taxes	Sep. 30, 2022
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes The effective tax rate for the nine months ended September 30, 2022 and 2021 benefited f rom $0.9 million a nd $2.4 million, respectively, of excess tax benefits associated with stock-based compensation arrangements. U.S. GAAP prescribes a recognition threshold and measurement attribute for the accounting and financial statement disclosure of tax positions taken or expected to be taken in a tax return. The evaluation of a tax position is a two-step process. The first step requires the Company to determine whether it is more likely than not that a tax position will be sustained upon examination based on the technical merits of the position. The second step requires the Company to recognize in the financial statements each tax position that meets the more likely than not criteria, measured at the amount of benefit that has a greater than 50% likelihood of being realized. The Company’s unrecognized tax benefits would affect the tax rate, if recognized. The Company includes the full amount of unrecognized tax benefits in income taxes payable in noncurrent liabilities in the Company's condensed consolidated balance sheets. The Company anticipates it is reasonably possible an increase or decrease in the amount of unrecognized tax benefits could be made in the next twelve months. However, the Company does not presently anticipate that any increase or decrease in unrecognized tax benefits will be material to the consolidated financial statements. As of September 30, 2022 and December 31, 2021, the Company recogniz ed $8.0 million and $7.3 million, respectively, in unrecognized tax benefits.

Subsequent Event

Subsequent Event	9 Months Ended
Subsequent Event	Sep. 30, 2022
Subsequent Events [Abstract]
Subsequent Event	Subsequent EventOn October 1, 2022, the Company purchased three wholly-owned home health agencies. Total consideration for the acquisition was $18.5 million.

Significant Accounting Polici_2

Significant Accounting Policies (Policies)	9 Months Ended
Significant Accounting Policies (Policies)	Sep. 30, 2022
Accounting Policies [Abstract]
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported revenue and expenses during the reporting period. Actual results could differ from those estimates.
Net Service Revenue	Net Service Revenue Net service revenue from contracts with customers is recognized in the period the performance obligations are satisfied under the Company's contracts by transferring the requested services to patients in amounts that reflect the consideration to which is expected to be received in exchange for providing patient care, which is the transaction price allocated to the services provided in accordance with Topic 606 and ASU 2015-14 , Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date (collectively, "ASC 606"). Net service revenue is recognized as performance obligations are satisfied, which can vary depending on the type of services provided. The performance obligation is the delivery of patient care in accordance with the requested services outlined in physicians' orders, which are based on specific goals for each patient. The performance obligations are associated with contracts in duration of less than one year; therefore, the optional exemption provided by ASC 606 was elected resulting in the Company not being required to disclose the aggregate amount of the transaction price allocated to the performance obligations that are unsatisfied or partially unsatisfied as of the end of the reporting period. The Company's unsatisfied or partially unsatisfied performance obligations are primarily completed when the patients are discharged and typically occur within days or weeks of the end of the period. The Company determines the transaction price based on gross charges for services provided, reduced by estimates for explicit and implicit price concessions. Explicit price concessions include contractual adjustments provided to patients and third-party payors. Implicit price concessions include discounts provided to self-pay, uninsured patients or other payors, adjustments resulting from regulatory reviews, audits, billing reviews and other matters. Subsequent changes to the estimate of the transaction price are recorded as adjustments to net service revenue in the period of change. Subsequent changes that are determined to be the result of an adverse change in the patient's ability to pay (i.e., change in credit risk) are recorded as a provision for doubtful accounts within general and administrative expenses. Explicit price concessions are recorded for the difference between our standard rates and the contracted rates to be realized from patients, third-party payors and others for services provided. Implicit price concessions are recorded for self-pay, uninsured patients and other payors by major payor class based on historical collection experience and current economic conditions, representing the difference between amounts billed and amounts expected to be collected. The Company assesses the ability to collect for the healthcare services provided at the time of patient admission based on the verification of the patient's insurance coverage under Medicare, Medicaid, and other commercial or managed care insurance programs. Amounts due from third-party payors, primarily commercial health insurers and government programs (Medicare and Medicaid), include variable consideration for retroactive revenue adjustments due to settlements of audits and reviews. The Company has determined estimates for price concessions related to regulatory reviews based on historical experience and success rates in the claim appeals and adjudication process. Revenue is recorded at amounts estimated to be realizable for services provided. Medicare The following describes the payment models in effect during the nine months ended September 30, 2022. Such payment models were subject to temporary adjustments made by CMS in response to COVID-19 pandemic as described elsewhere in this Quarterly Report on Form 10-Q. The 2% sequestration reduction adjustment was suspended for patient claims with dates of service through March 31, 2022. Medicare patient claims with dates of service between April 1 through June 30, 2022 had a 1% sequestration payment adjustment. Medicare patient claims with dates of service beginning July 1, 2022 had the full 2% sequestration payment adjustment. Home Health Services The Company records revenue as services are provided under the Patient Driven Groupings Model ("PDGM"). For each 30-day period, the patient is classified into one of 432 home health resource groups prior to receiving services. Each 30-day period is placed into a subgroup falling under the following categories: (i) timing being early or late, (ii) admission source being community or institutional, (iii) one of 12 clinical groupings based on the patient's principal diagnosis, (iv) functional impairment level of low, medium, or high, and (v) a co-morbidity adjustment of none, low, or high based on the patient's secondary diagnoses. Each 30-day period payment from Medicare reflects base payment adjustments for case-mix and geographic wage differences. In addition, payments may reflect one of three retroactive adjustments to the total reimbursement: (a) an outlier payment if the patient’s care was unusually costly; (b) a low utilization adjustment whereby the number of visits is dependent on the clinical grouping; and/or (c) a partial payment if the patient transferred to another provider or from another provider before completing the episode. The retroactive adjustments outlined above are recognized in net service revenue when the event causing the adjustment occurs and during the period in which the services are provided to the patient. The Company reviews these adjustments to ensure that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the retroactive adjustments is subsequently resolved. Net service revenue and related patient accounts receivable are recorded at amounts estimated to be realized from Medicare for services rendered. Hospice The Company records revenue based upon the date of service at amounts equal to the estimated payment rates. The Company receives one of four predetermined daily rates based upon the level of care provided by the Company, which can be routine care, general inpatient care, continuous home care, and respite care. There are two separate payment rates for routine care: payment for the first 60 days of care and care beyond 60 days. In addition to the two routine rates, the Company may also receive a service intensity add-on ("SIA"). The SIA is based on visits made in the last seven days of life by a registered nurse or medical social worker for patients in a routine level of care. The performance obligation is the delivery of hospice services to the patient, as determined by a physician, each day the patient is on hospice care. Adjustments to Medicare revenue are made from regulatory reviews, audits, billing reviews and other matters. The Company estimates the impact of these adjustments based on our historical experience. Hospice payments are subject to variable consideration through an inpatient cap and an overall Medicare payment cap. The inpatient cap relates to individual programs receiving more than 20% of their total Medicare reimbursement from inpatient care services, and the overall Medicare payment cap relates to individual programs receiving reimbursements in excess of a “cap amount,” determined by Medicare to be payment equal to 12 months of hospice care for the aggregate base of hospice patients, indexed for inflation. The determination for each cap is made annually based on the 12-month period ending on September 30 of each year. The Company monitors its limits on a provider-by-provider basis and records an estimate of its liability for reimbursements received in excess of the cap amount, if any, in the reporting period. Facility-Based Services Gross revenue is recorded as services are provided under the LTACH prospective payment system. Each patient is assigned a long-term care diagnosis-related group. The Company is paid a predetermined fixed amount intended to reflect the average cost of treating a Medicare LTACH patient classified in that particular long-term care diagnosis-related group. For selected LTACH patients, the amount may be further adjusted based on length-of-stay and facility-specific costs, as well as in instances where a patient is discharged and subsequently re-admitted, among other factors. The Company calculates the adjustment based on a historical average of these types of adjustments for LTACH claims paid. Similar to other Medicare prospective payment systems, the rate is also adjusted for geographic wage differences. Net service revenue adjustments resulting from reviews and audits of Medicare cost report settlements are considered implicit price concessions for LTACHs and are measured at expected value. Non-Medicare Revenues Other sources of net service revenue for all segments fall into Medicaid, managed care or other payors of the Company's services. Medicaid reimbursement is based on a predetermined fee schedule applied to each service provided. Therefore, revenue is recognized for Medicaid services as services are provided based on this fee schedule. The Company's managed care and other payors reimburse the Company based upon a predetermined fee schedule or an episodic basis, depending on the terms of the applicable contract. Accordingly, the Company recognizes revenue from managed care and other payors as services are provided, such costs are incurred, and estimates of expected payments are known for each different payor, thus the Company's revenue is recorded at the estimated transaction price. Contingent Service Revenues
Patient Accounts Receivable	Patient Accounts Receivable The Company reports patient accounts receivable from services rendered at their estimated transaction price, which includes price concessions based on the amounts expected from payors. The Company's patient accounts receivable is uncollateralized and primarily consist of amounts due from Medicare, Medicaid, other third-party payors, and to a lesser degree patients. The credit risk from other payors is limited due to the significance of Medicare as the primary payor. The Company believes the credit risk associated with its Medicare accounts is limited due to (i) the historical collection rate from Medicare and (ii) the fact
Earnings Per Share	Earnings Per Share Basic per share information is computed by dividing the relevant amounts from the condensed consolidated statements of income by the weighted-average number of shares outstanding during the period, under the treasury stock method. Diluted per share information is also computed using the treasury stock method, by dividing the relevant amounts from the condensed consolidated statements of income by the weighted-average number of shares outstanding plus potentially dilutive shares.

Basis of Presentation and Sig_2

Basis of Presentation and Significant Events (Tables)	9 Months Ended
Basis of Presentation and Significant Events (Tables)	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Net Service Revenues	The Company recognized the following amounts of net service revenue due to the suspension of the 2% sequestration payment adjustment and suspension of LTACH site-neutral payments (amounts in thousands): Three months ended September 30, Nine months ended September 30, 2022 2021 2022 2021 Suspension of 2% sequestration payment adjustment $ — $ 6,811 $ 9,952 $ 19,665 Suspension of LTACH site-neutral payment 4,918 5,749 17,070 18,230

Significant Accounting Polici_3

Significant Accounting Policies (Tables)	9 Months Ended
Significant Accounting Policies (Tables)	Sep. 30, 2022
Accounting Policies [Abstract]
Schedule of Percentage of Net Service Revenue Earned by Category of Payor	The following table sets forth the percentage of net service revenue earned by category of payor for the three and nine months ended September 30, 2022 and 2021: Three months ended Nine months ended 2022 2021 2022 2021 Home health: Medicare 59.7 % 62.1 % 59.4 % 62.8 % Managed Care, Commercial, and Other 40.3 37.9 40.6 37.2 100.0 % 100.0 % 100.0 % 100.0 % Hospice: Medicare 92.7 % 94.6 % 92.8 % 94.3 % Managed Care, Commercial, and Other 7.3 5.4 7.2 5.7 100.0 % 100.0 % 100.0 % 100.0 % Home and community-based services: Medicaid 38.3 % 32.1 % 36.8 % 31.1 % Managed Care, Commercial, and Other 61.7 67.9 63.2 68.9 100.0 % 100.0 % 100.0 % 100.0 % Facility-based services: Medicare 53.0 % 45.8 % 53.0 % 49.5 % Managed Care, Commercial, and Other 47.0 54.2 47.0 50.5 100.0 % 100.0 % 100.0 % 100.0 % HCI: Medicare 2.8 % 6.0 % 5.4 % 11.4 % Managed Care, Commercial, and Other 97.2 94.0 94.6 88.6 100.0 % 100.0 % 100.0 % 100.0 %
Schedule of Shares Used in Computation of Basic and Diluted Per Share Information	The following table sets forth shares used in the computation of basic and diluted per share information and, with respect to the data provided for the three and nine months ended September 30, 2022 and 2021 (amounts in thousands): Three months ended Nine months ended 2022 2021 2022 2021 Weighted average number of shares outstanding for basic per share calculation 30,565 31,238 30,527 31,205 Effect of dilutive potential shares: Nonvested stock 141 196 112 217 Adjusted weighted average shares for diluted per share calculation 30,706 31,434 30,639 31,422 Anti-dilutive shares 87 6 264 118

Acquisitions (Tables)

Acquisitions (Tables)	9 Months Ended
Acquisitions (Tables)	Sep. 30, 2022
Business Combination and Asset Acquisition [Abstract]
Schedule of recognized identified assets acquired and liabilities assumed	The following table summarizes the preliminary amounts of the assets acquired and liabilities assumed at their acquisition date, as well as their fair value at the acquisition date and the noncontrolling interest acquired during the nine months ended September 30, 2022 (amounts in thousands): Consideration Cash $ 2,570 Fair value of total consideration transferred Recognized amounts of identifiable assets acquired and liabilities assumed: Trade name $ 453 Certificates of need/licenses 357 Other liabilities (227) Total identifiable assets and liabilities $ 583 Noncontrolling interest $ 707 Goodwill, including noncontrolling interest of $504 $ 2,694

Goodwill and Intangibles (Table

Goodwill and Intangibles (Tables)	9 Months Ended
Goodwill and Intangibles (Tables)	Sep. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Changes in Recorded Goodwill by Reporting Unit	The changes in recorded goodwill and intangible assets by reporting unit for the nine months ended September 30, 2022 were as follows (amounts in thousands): Home health reporting unit Hospice Home and community-based services Facility-based HCI reporting unit Total Goodwill: Balance as of December 31, 2021 $ 968,435 $ 556,332 $ 167,027 $ 15,770 $ 40,862 $ 1,748,426 Net working capital adjustments — 1,440 — — — 1,440 Acquisitions 2,190 — — — — 2,190 Noncontrolling interests 504 — — — — 504 Disposals (440) (1,460) (240) — — (2,140) Balance as of September 30, 2022 $ 970,689 $ 556,312 $ 166,787 $ 15,770 $ 40,862 $ 1,750,420 Intangible assets: Balance as of December 31, 2021 $ 237,979 $ 117,340 $ 24,245 $ 5,919 $ 14,519 $ 400,002 Acquisitions 1,010 — — — — 1,010 Amortization (1,589) (1,346) (8) (334) (436) (3,713) Disposals (491) (1,217) (282) — — (1,990) Balance as of September 30, 2022 $ 236,909 $ 114,777 $ 23,955 $ 5,585 $ 14,083 $ 395,309
Schedule of Changes in Intangible Assets, Indefinite	The following tables summarize the changes in intangible assets during the nine months ended September 30, 2022 and December 31, 2021 (amounts in thousands): 2022 2021 Indefinite-lived intangible assets: Trade names $ 208,160 $ 207,780 Certificates of need/licenses 172,395 173,955 Net total $ 380,555 $ 381,735 Definite-lived intangible assets: Trade names Gross carrying amount $ 11,273 $ 11,073 Accumulated amortization (10,559) (9,606) Net total $ 714 $ 1,467 Non-compete agreements Gross carrying amount $ 14,524 $ 14,524 Accumulated amortization (9,495) (7,172) Net total $ 5,029 $ 7,352 Customer relationships Gross carrying amount $ 11,822 $ 11,822 Accumulated amortization (2,811) (2,374) Net total $ 9,011 $ 9,448 Total definite-lived intangible assets Gross carrying amount $ 37,619 $ 37,419 Accumulated amortization (22,865) (19,152) Net total $ 14,754 $ 18,267 Total intangible assets: Gross carrying amount $ 418,174 $ 419,154 Accumulated amortization (22,865) (19,152) Net total $ 395,309 $ 400,002
Schedule of Changes in Intangible Assets, Finite	The following tables summarize the changes in intangible assets during the nine months ended September 30, 2022 and December 31, 2021 (amounts in thousands): 2022 2021 Indefinite-lived intangible assets: Trade names $ 208,160 $ 207,780 Certificates of need/licenses 172,395 173,955 Net total $ 380,555 $ 381,735 Definite-lived intangible assets: Trade names Gross carrying amount $ 11,273 $ 11,073 Accumulated amortization (10,559) (9,606) Net total $ 714 $ 1,467 Non-compete agreements Gross carrying amount $ 14,524 $ 14,524 Accumulated amortization (9,495) (7,172) Net total $ 5,029 $ 7,352 Customer relationships Gross carrying amount $ 11,822 $ 11,822 Accumulated amortization (2,811) (2,374) Net total $ 9,011 $ 9,448 Total definite-lived intangible assets Gross carrying amount $ 37,619 $ 37,419 Accumulated amortization (22,865) (19,152) Net total $ 14,754 $ 18,267 Total intangible assets: Gross carrying amount $ 418,174 $ 419,154 Accumulated amortization (22,865) (19,152) Net total $ 395,309 $ 400,002

Stockholder's Equity (Tables)

Stockholder's Equity (Tables)	9 Months Ended
Stockholder's Equity (Tables)	Sep. 30, 2022
Equity [Abstract]
Schedule of Share Grants Activity	The following table represents the share grants activity for the nine months ended September 30, 2022: Restricted stock Options Number of shares Weighted Number of shares Weighted Share grants outstanding as of December 31, 2021 415,816 $ 122.40 74,235 $ 42.07 Granted 202,045 139.64 — — Vested or exercised (162,749) 143.35 (13,986) 31.27 Share grants outstanding as of September 30, 2022 455,112 $ 134.44 60,249 $ 43.05
Schedule of Shares of Common Stock Issued Under Employee Stock Purchase Plan	The table below details the shares of common stock issued during 2022: Number of Per share Shares available as of December 31, 2021 104,344 Shares issued during the three months ended March 31, 2022 5,353 $ 130.37 Shares issued during the three months ended June 30, 2022 3,342 $ 160.17 Shares issued during the three months ended September 30, 2022 4,104 $ 147.95 Shares available as of September 30, 2022 91,545

Noncontrolling interests (Table

Noncontrolling interests (Tables)	9 Months Ended
Noncontrolling interests (Tables)	Sep. 30, 2022
Noncontrolling Interest [Abstract]
Schedule of Activity of Noncontrolling Interest-Redeemable	The following table summarizes the activity of noncontrolling interest-redeemable for the nine months ended September 30, 2022 (amounts in thousands): Balance as of December 31, 2021 $ 17,501 Net income attributable to noncontrolling interest-redeemable 6,991 Noncontrolling interest-redeemable distributions (7,514) Balance as of September 30, 2022 $ 16,978

Leases (Tables)

Leases (Tables)	9 Months Ended
Leases (Tables)	Sep. 30, 2022
Leases [Abstract]
Schedule of Operating Lease Right of Use Assets and Related Lease Payables	The following table summarizes the operating lease right of use assets and related lease payables in our condensed consolidated balance sheets as of September 30, 2022 and December 31, 2021 (amounts in thousands): September 30, 2022 December 31, 2021 Operating lease right of use asset $ 108,975 $ 113,399 Current operating lease liabilities 36,998 37,630 Long-term operating lease liabilities 74,992 78,688
Schedule of Lease Cost	The components of lease costs for operating leases for the three and nine months ended September 30, 2022 and 2021 were as follows (amounts in thousands): Three months ended September 30, Nine months ended September 30, 2022 2021 2022 2021 Operating lease cost $ 14,033 $ 12,791 $ 42,800 $ 37,096 Short-term lease cost 908 927 2,712 2,697 Variable lease cost 1,246 997 3,350 3,058 Total lease costs $ 16,187 $ 14,715 $ 48,862 $ 42,851
Schedule of Maturities of Operating Lease Liabilities	Maturities of operating lease liabilities as of September 30, 2022 were as follows (amounts in thousands): Month ending September 30, 2022 $ 11,073 2023 38,472 2024 29,629 2025 21,006 Thereafter 20,224 Total future minimum lease payments 120,404 Less: Imputed interest (8,414) Total $ 111,990

Segment Information (Tables)

Segment Information (Tables)	9 Months Ended
Segment Information (Tables)	Sep. 30, 2022
Segment Reporting [Abstract]
Schedule of Segment Information	The following tables summarize the Company’s segment information for the three and nine months ended September 30, 2022 and 2021 (amounts in thousands): Three months ended September 30, 2022 Home health services Hospice services Home and community-based services Facility-based services HCI Total Net service revenue $ 373,335 $ 103,799 $ 47,978 $ 31,441 $ 20,360 $ 576,913 Cost of service revenue (excluding depreciation and amortization) 217,790 68,951 35,727 22,549 2,755 347,772 General and administrative expenses 126,052 32,384 11,893 12,098 6,624 189,051 Impairment of intangibles and other — 1,590 469 — — 2,059 Operating income (loss) 29,493 874 (111) (3,206) 10,981 38,031 Interest expense (6,347) (1,356) (808) (362) (180) (9,053) Income (loss) before income taxes and noncontrolling interest 23,146 (482) (919) (3,568) 10,801 28,978 Income tax expense (benefit) 5,723 (439) (165) (927) 2,774 6,966 Net income (loss) 17,423 (43) (754) (2,641) 8,027 22,012 Less net income (loss) attributable to non controlling interests 3,838 1,269 (125) (439) 160 4,703 Net income (loss) attributable to LHC Group, Inc.'s common stockholder $ 13,585 $ (1,312) $ (629) $ (2,202) $ 7,867 $ 17,309 Total assets $ 1,717,209 $ 798,668 $ 238,082 $ 80,223 $ 79,972 $ 2,914,154 Three months ended September 30, 2021 Home health services Hospice services Home and community-based services Facility-based services HCI Total Net service revenue $ 386,699 $ 82,653 $ 45,800 $ 32,415 $ 17,884 $ 565,451 Cost of service revenue (excluding depreciation and amortization) 230,839 51,631 34,386 23,725 3,281 343,862 General and administrative expenses 126,695 22,548 11,764 11,050 4,387 176,444 Operating income (loss) 29,165 8,474 (350) (2,360) 10,216 45,145 Interest expense (811) (139) (109) (54) (22) (1,135) Income (loss) before income taxes and noncontrolling interest 28,354 8,335 (459) (2,414) 10,194 44,010 Income tax expense (benefit) 6,407 1,874 (99) (554) 2,522 10,150 Net income (loss) 21,947 6,461 (360) (1,860) 7,672 33,860 Less net income (loss) attributable to noncontrolling interests 5,157 1,085 77 (187) (6) 6,126 Net income (loss) attributable to LHC Group, Inc.'s common stockholders $ 16,790 $ 5,376 $ (437) $ (1,673) $ 7,678 $ 27,734 Total assets $ 1,632,670 $ 681,954 $ 239,452 $ 83,276 $ 75,334 $ 2,712,686 Nine months ended September 30, 2022 Home health services Hospice services Home and community-based services Facility-based services HCI Total Net service revenue $ 1,154,009 $ 308,322 $ 137,036 $ 94,289 $ 30,945 $ 1,724,601 Cost of service revenue (excluding depreciation and amortization) 674,508 202,864 96,470 69,584 8,667 1,052,093 General and administrative expenses 387,482 97,152 35,755 35,737 13,674 569,800 Impairment of intangibles and other 930 2,677 523 — — 4,130 Operating income (loss) 91,089 5,629 4,288 (11,032) 8,604 98,578 Interest expense (13,805) (2,803) (1,785) (851) (387) (19,631) Income (loss) before income taxes and noncontrolling interest 77,284 2,826 2,503 (11,883) 8,217 78,947 Income tax expense (benefit) 17,057 (3) 680 (2,849) 2,129 17,014 Net income (loss) 60,227 2,829 1,823 (9,034) 6,088 61,933 Less net income (loss) attributable to non controlling interests 12,758 2,837 (74) (1,085) 150 14,586 Net income (loss) attributable to LHC Group, Inc.'s common stockholder $ 47,469 $ (8) $ 1,897 $ (7,949) $ 5,938 $ 47,347 Nine months ended September 30, 2021 Home health services Hospice services Home and community-based services Facility-based services HCI Total Net service revenue $ 1,157,061 $ 209,191 $ 143,332 $ 96,814 $ 29,795 $ 1,636,193 Cost of service revenue (excluding depreciation and amortization) 663,137 129,848 103,941 65,360 9,720 972,006 General and administrative expenses 369,337 58,789 35,216 33,213 10,199 506,754 Impairment of intangibles and other 937 — — — — 937 Operating income (loss) 123,650 20,554 4,175 (1,759) 9,876 156,496 Interest expense (1,099) (195) (143) (73) (31) (1,541) Income (loss) before income taxes and noncontrolling interest 122,551 20,359 4,032 (1,832) 9,845 154,955 Income tax expense (benefit) 26,003 4,221 889 (649) 2,445 32,909 Net income (loss) 96,548 16,138 3,143 (1,183) 7,400 122,046 Less net income (loss) attributable to non controlling interests 17,506 3,308 441 792 (37) 22,010 Net income (loss) attributable to LHC Group, Inc.'s common stockholder $ 79,042 $ 12,830 $ 2,702 $ (1,975) $ 7,437 $ 100,036

Basis of Presentation and Sig_3

Basis of Presentation and Significant Events - Organization (Details)	9 Months Ended
	Sep. 30, 2022 state location segment
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of operating segments \| segment	5
Number of service providers operated \| location	942
Number of states in which company operates \| state	37

Basis of Presentation and Sig_4

Basis of Presentation and Significant Events - CAAP (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Contract liabilities - deferred revenue	$ 4,840	$ 106,489
Recoupment of fund	101,600
Employee-related liabilities	$ 26,800

Basis of Presentation and Sig_5

Basis of Presentation and Significant Events - Schedule of Net Service Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Suspension of 2% sequestration payment adjustment	$ 0	$ 6,811	$ 9,952	$ 19,665
Suspension of LTACH site-neutral payment	$ 4,918	$ 5,749	$ 17,070	$ 18,230

Significant Accounting Polici_4

Significant Accounting Policies - Percentage of Net Service Revenue Earned by Category of Payor (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Home health services
Disaggregation of Revenue [Line Items]
Percentage of net service revenue	100%	100%	100%	100%
Hospice services
Disaggregation of Revenue [Line Items]
Percentage of net service revenue	100%	100%	100%	100%
Home and community-based services
Disaggregation of Revenue [Line Items]
Percentage of net service revenue	100%	100%	100%	100%
Facility-based services
Disaggregation of Revenue [Line Items]
Percentage of net service revenue	100%	100%	100%	100%
HCI
Disaggregation of Revenue [Line Items]
Percentage of net service revenue	100%	100%	100%	100%
Medicare \| Home health services
Disaggregation of Revenue [Line Items]
Percentage of net service revenue	59.70%	62.10%	59.40%	62.80%
Medicare \| Hospice services
Disaggregation of Revenue [Line Items]
Percentage of net service revenue	92.70%	94.60%	92.80%	94.30%
Medicare \| Facility-based services
Disaggregation of Revenue [Line Items]
Percentage of net service revenue	53%	45.80%	53%	49.50%
Medicare \| HCI
Disaggregation of Revenue [Line Items]
Percentage of net service revenue	2.80%	6%	5.40%	11.40%
Managed Care, Commercial, and Other \| Home health services
Disaggregation of Revenue [Line Items]
Percentage of net service revenue	40.30%	37.90%	40.60%	37.20%
Managed Care, Commercial, and Other \| Hospice services
Disaggregation of Revenue [Line Items]
Percentage of net service revenue	7.30%	5.40%	7.20%	5.70%
Managed Care, Commercial, and Other \| Home and community-based services
Disaggregation of Revenue [Line Items]
Percentage of net service revenue	61.70%	67.90%	63.20%	68.90%
Managed Care, Commercial, and Other \| Facility-based services
Disaggregation of Revenue [Line Items]
Percentage of net service revenue	47%	54.20%	47%	50.50%
Managed Care, Commercial, and Other \| HCI
Disaggregation of Revenue [Line Items]
Percentage of net service revenue	97.20%	94%	94.60%	88.60%
Medicaid \| Home and community-based services
Disaggregation of Revenue [Line Items]
Percentage of net service revenue	38.30%	32.10%	36.80%	31.10%

Significant Accounting Polici_5

Significant Accounting Policies - Additional Information (Details) $ in Millions	9 Months Ended
	Sep. 30, 2022 USD ($) adjustment separate_payment periodicRate group	Sep. 30, 2021 USD ($)	Sep. 30, 2020 USD ($)
Accounting Policies [Abstract]
Medicare sequestration reduction adjustment	2%
Number of days from date RAP paid to submit final Medicare bill	30 days
Number of Medicare home health resource groups \| group	432
Number of medicare clinical groups \| group	12
Number of retroactive adjustments \| adjustment	3
Selected hospice, periodic rate used to calculate revenue \| periodicRate	1
Number of hospice, periodic rates used to calculate revenue \| periodicRate	4
Number of separate payment rates \| separate_payment	2
Percentage subject to inpatient cap	20%
Determination period for hospice Medicare inpatient reimbursement cap	12 months
HCI
Segment Reporting Information [Line Items]
Revenue recognized		$ 15.6	$ 12.1
Post Acute Management Services Company
Noncontrolling Interest [Line Items]
Cost method investment	$ 15
Jumpstart Nova Fund, LP
Noncontrolling Interest [Line Items]
Cost method investment	0.1	0.1
LHCC Aging Innovations Fund I, LP
Noncontrolling Interest [Line Items]
Cost method investment	$ 0.2
Healthcare Analytics Company
Noncontrolling Interest [Line Items]
Cost method investment		$ 10

Significant Accounting Polici_6

Significant Accounting Policies - Shares Used in Computation of Basic and Diluted Per Share Information (Details) - shares shares in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Accounting Policies [Abstract]
Weighted average number of shares outstanding for basic per share calculation (in shares)	30,565	31,238	30,527	31,205
Effect of dilutive potential shares:
Nonvested restricted stock (in shares)	141	196	112	217
Adjusted weighted average shares for diluted per share calculation (in shares)	30,706	31,434	30,639	31,422
Anti-dilutive shares (in shares)	87	6	264	118

Acquisitions - Additional Infor

Acquisitions - Additional Information (Details) $ in Millions		9 Months Ended
	May 01, 2022 USD ($) location	Sep. 30, 2022 USD ($)
Schedule of Equity Method Investments [Line Items]
Due to government entities, reduction		$ 3.2
Heart of Hospice
Schedule of Equity Method Investments [Line Items]
Account receivable adjustment		1.5
Brookdale Health Care Services
Schedule of Equity Method Investments [Line Items]
Net working capital adjustment		$ 3.1
Majority Ownership of a Home Health Agency from Archbold Medical Center
Schedule of Equity Method Investments [Line Items]
Number of locations of facilities \| location	2
Consideration transferred	$ 3.7

Acquisitions (Details)

Acquisitions (Details) - USD ($) $ in Thousands	9 Months Ended
Acquisitions (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Recognized amounts of identifiable assets acquired and liabilities assumed:
Goodwill	$ 1,750,420	$ 1,748,426
Majority Ownership of a Home Health Agency from Archbold Medical Center
Business Combination, Consideration Transferred [Abstract]
Consideration	2,570
Recognized amounts of identifiable assets acquired and liabilities assumed:
Other liabilities	(227)
Total identifiable assets and liabilities	583
Noncontrolling interest	707
Goodwill	2,694
Goodwill noncontrolling interest portion	504
Majority Ownership of a Home Health Agency from Archbold Medical Center \| Trade names
Recognized amounts of identifiable assets acquired and liabilities assumed:
Indefinite-lived intangible assets	453
Majority Ownership of a Home Health Agency from Archbold Medical Center \| Certificates of need/licenses
Recognized amounts of identifiable assets acquired and liabilities assumed:
Indefinite-lived intangible assets	$ 357

Goodwill and Intangibles - Sche

Goodwill and Intangibles - Schedule of Changes in Recorded Goodwill by Reporting Unit (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Goodwill:
Goodwill, beginning balance			$ 1,748,426
Net working capital adjustments			1,440
Acquisitions			2,190
Noncontrolling interests			504
Disposals			(2,140)
Goodwill, ending balance	$ 1,750,420		1,750,420
Intangible assets:
Intangible assets, beginning balance (excluding goodwill)			400,002
Acquisitions			1,010
Amortization	(1,000)	$ (400)	(3,713)	$ (1,000)
Disposals			(1,990)
Intangible assets, ending balance (excluding goodwill)	395,309		395,309
Home health reporting unit
Goodwill:
Goodwill, beginning balance			968,435
Net working capital adjustments			0
Acquisitions			2,190
Noncontrolling interests			504
Disposals			(440)
Goodwill, ending balance	970,689		970,689
Intangible assets:
Intangible assets, beginning balance (excluding goodwill)			237,979
Acquisitions			1,010
Amortization			(1,589)
Disposals			(491)
Intangible assets, ending balance (excluding goodwill)	236,909		236,909
Hospice reporting unit
Goodwill:
Goodwill, beginning balance			556,332
Net working capital adjustments			1,440
Acquisitions			0
Noncontrolling interests			0
Disposals			(1,460)
Goodwill, ending balance	556,312		556,312
Intangible assets:
Intangible assets, beginning balance (excluding goodwill)			117,340
Acquisitions			0
Amortization			(1,346)
Disposals			(1,217)
Intangible assets, ending balance (excluding goodwill)	114,777		114,777
Home and community-based services reporting unit
Goodwill:
Goodwill, beginning balance			167,027
Net working capital adjustments			0
Acquisitions			0
Noncontrolling interests			0
Disposals			(240)
Goodwill, ending balance	166,787		166,787
Intangible assets:
Intangible assets, beginning balance (excluding goodwill)			24,245
Acquisitions			0
Amortization			(8)
Disposals			(282)
Intangible assets, ending balance (excluding goodwill)	23,955		23,955
Facility-based reporting unit
Goodwill:
Goodwill, beginning balance			15,770
Net working capital adjustments			0
Acquisitions			0
Noncontrolling interests			0
Disposals			0
Goodwill, ending balance	15,770		15,770
Intangible assets:
Intangible assets, beginning balance (excluding goodwill)			5,919
Acquisitions			0
Amortization			(334)
Disposals			0
Intangible assets, ending balance (excluding goodwill)	5,585		5,585
HCI reporting unit
Goodwill:
Goodwill, beginning balance			40,862
Net working capital adjustments			0
Acquisitions			0
Noncontrolling interests			0
Disposals			0
Goodwill, ending balance	40,862		40,862
Intangible assets:
Intangible assets, beginning balance (excluding goodwill)			14,519
Acquisitions			0
Amortization			(436)
Disposals			0
Intangible assets, ending balance (excluding goodwill)	$ 14,083		$ 14,083

Goodwill and Intangibles - Addi

Goodwill and Intangibles - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Finite-Lived Intangible Assets [Line Items]
Goodwill impairment loss			$ 2,100	$ 20
Amortization of intangible assets	$ 1,000	$ 400	$ 3,713	1,000
Trade names
Finite-Lived Intangible Assets [Line Items]
Useful life			7 years		7 years 9 months 18 days
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Useful life			15 years 6 months		16 years 3 months 18 days
Non-compete agreements
Finite-Lived Intangible Assets [Line Items]
Useful life			4 years 2 months 12 days		4 years 10 months 24 days
Medicare Licenses
Finite-Lived Intangible Assets [Line Items]
Impairment of intangible asset			$ 2,000	$ 900

Goodwill and Intangibles - Summ

Goodwill and Intangibles - Summary of Changes in Intangible Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Finite-Lived Intangible Assets [Line Items]
Indefinite-lived intangible assets:	$ 380,555	$ 381,735
Gross carrying amount, definite-lived intangible assets	37,619	37,419
Accumulated amortization	(22,865)	(19,152)
Net total	14,754	18,267
Gross carrying amount, intangible assets	418,174	419,154
Net total	395,309	400,002
Trade names
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount, definite-lived intangible assets	11,273	11,073
Accumulated amortization	(10,559)	(9,606)
Net total	714	1,467
Non-compete agreements
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount, definite-lived intangible assets	14,524	14,524
Accumulated amortization	(9,495)	(7,172)
Net total	5,029	7,352
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount, definite-lived intangible assets	11,822	11,822
Accumulated amortization	(2,811)	(2,374)
Net total	9,011	9,448
Trade names
Finite-Lived Intangible Assets [Line Items]
Indefinite-lived intangible assets:	208,160	207,780
Certificates of need/licenses
Finite-Lived Intangible Assets [Line Items]
Indefinite-lived intangible assets:	$ 172,395	$ 173,955

Debt - Additional Information (

Debt - Additional Information (Details)		9 Months Ended
Debt - Additional Information (Details)	Aug. 03, 2021 USD ($) instrument	Sep. 30, 2022 USD ($)	Dec. 31, 2021 USD ($)
Debt Instrument [Line Items]
Line of credit facility drawn		$ 738,000,000	$ 661,197,000
2021 Amended Credit Agreement \| Line of Credit
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 800,000,000		1,000,000,000
Credit facility maximum borrowing capacity under accordion feature	500,000,000		300,000,000
2021 Amended Credit Agreement \| Letter of Credit
Debt Instrument [Line Items]
Letter of credit, sub-limit amount	$ 75,000,000
Interest rate percentage		4.98%
Line of credit facility drawn		$ 738,000,000	661,200,000
Letter of credit outstanding		24,300,000	$ 24,300,000
Available credit under agreement		$ 237,700,000
2021 Amended Credit Agreement \| Letter of Credit \| Minimum
Debt Instrument [Line Items]
Commitment fee rates for unused commitments	0.15%
2021 Amended Credit Agreement \| Letter of Credit \| Maximum
Debt Instrument [Line Items]
Commitment fee rates for unused commitments	0.30%
2021 Amended Credit Agreement \| Letter of Credit \| LIBOR
Debt Instrument [Line Items]
Line of credit facility interest rate		5.13%
2021 Amended Credit Agreement \| Letter of Credit \| LIBOR \| Minimum
Debt Instrument [Line Items]
Line of credit facility interest rate	1.25%
2021 Amended Credit Agreement \| Letter of Credit \| LIBOR \| Maximum
Debt Instrument [Line Items]
Line of credit facility interest rate	2%
2021 Amended Credit Agreement \| Letter of Credit \| Base Rate
Debt Instrument [Line Items]
Line of credit facility interest rate		7.25%
2021 Amended Credit Agreement \| Letter of Credit \| Base Rate \| Minimum
Debt Instrument [Line Items]
Line of credit facility interest rate	0.25%
2021 Amended Credit Agreement \| Letter of Credit \| Base Rate \| Maximum
Debt Instrument [Line Items]
Line of credit facility interest rate	1%
2021 Amended Credit Agreement \| Letter of Credit \| Eurodollar
Debt Instrument [Line Items]
Line of credit facility, borrowing outstanding \| instrument	15

Stockholder's Equity - Addition

Stockholder's Equity - Additional Information (Details) - USD ($)	9 Months Ended		12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2013	Dec. 31, 2006	Dec. 06, 2021	Dec. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total unrecognized compensation cost related to nonvested shares of common stock granted	$ 49,600,000
Weighted average period of cost recognized	3 years 3 months
Compensation expense related to nonvested stock grants	$ 15,300,000	$ 11,700,000
Price of shares issued under Employee Stock Purchase Plan as a percentage of FMV				95%
Number of shares reserved for the Employee Stock Purchase Plan (in shares)				250,000
Additional shares authorized for issuance (in shares)			250,000
Shares redeemed to satisfy personal tax obligations (in shares)	28,802
Treasury shares redeemed to pay income tax	$ 5,000,000
Number of shares forfeited	5,268
Shares redeemed (in shares)	6,249
Stock redeemed, value	$ 200,000
Stock repurchase program, authorized amount					$ 250,000,000
Treasury shares acquired (in shares)	190,622
Treasury stock, value, acquired, cost method	$ 25,500,000
Independent Directors
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Nonvested stock grants to Independent directors (in shares)	8,800
Percentage of directors' stock grant vested on one year anniversary date	100%
2018 Long-Term Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserved for issuance (in shares)						2,210,544
Common stock available for issuance (in shares)						1,544,734
Period of vested shares	5 years
2018 Long-Term Incentive Plan \| Employee
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Nonvested stock grants to employees (in shares)	182,310
2018 Long-Term Incentive Plan \| Consultant
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Nonvested stock grants to employees (in shares)	10,935
Second Amended and Restated 2005 Non-Employee Directors Compensation Plan \| Independent Directors
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Period of vested shares	1 year

Stockholder's Equity - Nonveste

Stockholder's Equity - Nonvested Stock Activity (Details)	9 Months Ended
Stockholder's Equity - Nonvested Stock Activity (Details)	Sep. 30, 2022 $ / shares shares
Restricted stock
Number of shares
Share grants outstanding, beginning balance \| shares	415,816
Granted (in shares) \| shares	202,045
Vested or exercised (in shares) \| shares	(162,749)
Share grants outstanding, ending balance \| shares	455,112
Weighted average grant date fair value
Share grants beginning balance, (in dollars per share) \| $ / shares	$ 122.40
Granted (in dollars per share) \| $ / shares	139.64
Vested or exercised (in dollars per share) \| $ / shares	143.35
Share grants ending balance, (in dollars per share) \| $ / shares	$ 134.44
Options
Number of shares
Share grants outstanding, beginning balance \| shares	74,235
Granted (in shares) \| shares	0
Vested or exercised (in shares) \| shares	(13,986)
Share grants outstanding, ending balance \| shares	60,249
Weighted average grant date fair value
Share grants outstanding, beginning balance (in dollars per share) \| $ / shares	$ 42.07
Granted (in dollars per share) \| $ / shares	0
Vested or exercised (in dollars per share) \| $ / shares	31.27
Share grants outstanding, ending balance (in dollars per share) \| $ / shares	$ 43.05

Stockholder's Equity - Shares o

Stockholder's Equity - Shares of Common Stock Issued Under Employee Stock Purchase Plan (Details) - $ / shares	3 Months Ended
	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Number of shares available, beginning balance (in shares)			104,344
Shares issued during period (in shares)	4,104	3,342	5,353
Number of shares available, ending balance (in shares)	91,545
Per share price of shares issued during period (in dollars per share)	$ 147.95	$ 160.17	$ 130.37

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Other assets, amount from government payors	$ 12	$ 16.9
Period of joint venture buy/sell option	30 days

Noncontrolling interests - Summ

Noncontrolling interests - Summary of Activity of Noncontrolling Interest-Redeemable (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]
Balance as of December 31, 2021			$ 17,501
Net income attributable to noncontrolling interest-redeemable	$ 2,000	$ 2,900	6,991	$ 9,100
Noncontrolling interest-redeemable distributions			(7,514)
Balance as of September 30, 2022	$ 16,978		$ 16,978

Leases - Additional information

Leases - Additional information (Details)	Sep. 30, 2022
Lessee, Lease, Description [Line Items]
Operating lease term	5 years
Weighted-average remaining lease term	3 years 7 months 17 days
Weighted-average discount rate	4.11%
Minimum
Lessee, Lease, Description [Line Items]
Renewal term	1 year
Maximum
Lessee, Lease, Description [Line Items]
Renewal term	9 years

Leases - Right of Use and Liabi

Leases - Right of Use and Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Leases [Abstract]
Operating lease right of use asset	$ 108,975	$ 113,399
Current operating lease liabilities	36,998	37,630
Long-term operating lease liabilities	$ 74,992	$ 78,688

Leases - Lease Cost (Details)

Leases - Lease Cost (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
Leases - Lease Cost (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Leases [Abstract]
Operating lease cost	$ 14,033	$ 12,791	$ 42,800	$ 37,096
Short-term lease cost	908	927	2,712	2,697
Variable lease cost	1,246	997	3,350	3,058
Total lease costs	$ 16,187	$ 14,715	$ 48,862	$ 42,851

Leases - Lease Maturities (Deta

Leases - Lease Maturities (Details) $ in Thousands	Sep. 30, 2022 USD ($)
Leases [Abstract]
2022	$ 11,073
2023	38,472
2024	29,629
2025	21,006
Thereafter	20,224
Total future minimum lease payments	120,404
Less: Imputed interest	(8,414)
Total	$ 111,990

Segment Information - Summary o

Segment Information - Summary of segment Information (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Segment Reporting, Disclosure of Entity's Reportable Segments [Abstract]
Net service revenue	$ 576,913	$ 565,451	$ 1,724,601	$ 1,636,193
Cost of service revenue (excluding depreciation and amortization)	347,772	343,862	1,052,093	972,006
General and administrative expenses	189,051	176,444	569,800	506,754
Impairment of intangibles and other	2,059		4,130	937
Operating income	38,031	45,145	98,578	156,496
Interest expense	(9,053)	(1,135)	(19,631)	(1,541)
Income (loss) before income taxes and noncontrolling interest	28,978	44,010	78,947	154,955
Income tax expense (benefit)	6,966	10,150	17,014	32,909
Net income	22,012	33,860	61,933	122,046
Less net income (loss) attributable to non controlling interests	4,703	6,126	14,586	22,010
Net income attributable to LHC Group, Inc.’s common stockholders	17,309	27,734	47,347	100,036
Total assets	2,914,154	2,712,686	2,914,154	2,712,686	$ 2,895,621
Home health services
Segment Reporting, Disclosure of Entity's Reportable Segments [Abstract]
Net service revenue	373,335	386,699	1,154,009	1,157,061
Cost of service revenue (excluding depreciation and amortization)	217,790	230,839	674,508	663,137
General and administrative expenses	126,052	126,695	387,482	369,337
Impairment of intangibles and other	0		930	937
Operating income	29,493	29,165	91,089	123,650
Interest expense	(6,347)	(811)	(13,805)	(1,099)
Income (loss) before income taxes and noncontrolling interest	23,146	28,354	77,284	122,551
Income tax expense (benefit)	5,723	6,407	17,057	26,003
Net income	17,423	21,947	60,227	96,548
Less net income (loss) attributable to non controlling interests	3,838	5,157	12,758	17,506
Net income attributable to LHC Group, Inc.’s common stockholders	13,585	16,790	47,469	79,042
Total assets	1,717,209	1,632,670	1,717,209	1,632,670
Hospice services
Segment Reporting, Disclosure of Entity's Reportable Segments [Abstract]
Net service revenue	103,799	82,653	308,322	209,191
Cost of service revenue (excluding depreciation and amortization)	68,951	51,631	202,864	129,848
General and administrative expenses	32,384	22,548	97,152	58,789
Impairment of intangibles and other	1,590		2,677	0
Operating income	874	8,474	5,629	20,554
Interest expense	(1,356)	(139)	(2,803)	(195)
Income (loss) before income taxes and noncontrolling interest	(482)	8,335	2,826	20,359
Income tax expense (benefit)	(439)	1,874	(3)	4,221
Net income	(43)	6,461	2,829	16,138
Less net income (loss) attributable to non controlling interests	1,269	1,085	2,837	3,308
Net income attributable to LHC Group, Inc.’s common stockholders	(1,312)	5,376	(8)	12,830
Total assets	798,668	681,954	798,668	681,954
Home and community-based services
Segment Reporting, Disclosure of Entity's Reportable Segments [Abstract]
Net service revenue	47,978	45,800	137,036	143,332
Cost of service revenue (excluding depreciation and amortization)	35,727	34,386	96,470	103,941
General and administrative expenses	11,893	11,764	35,755	35,216
Impairment of intangibles and other	469		523	0
Operating income	(111)	(350)	4,288	4,175
Interest expense	(808)	(109)	(1,785)	(143)
Income (loss) before income taxes and noncontrolling interest	(919)	(459)	2,503	4,032
Income tax expense (benefit)	(165)	(99)	680	889
Net income	(754)	(360)	1,823	3,143
Less net income (loss) attributable to non controlling interests	(125)	77	(74)	441
Net income attributable to LHC Group, Inc.’s common stockholders	(629)	(437)	1,897	2,702
Total assets	238,082	239,452	238,082	239,452
Facility-based services
Segment Reporting, Disclosure of Entity's Reportable Segments [Abstract]
Net service revenue	31,441	32,415	94,289	96,814
Cost of service revenue (excluding depreciation and amortization)	22,549	23,725	69,584	65,360
General and administrative expenses	12,098	11,050	35,737	33,213
Impairment of intangibles and other	0		0	0
Operating income	(3,206)	(2,360)	(11,032)	(1,759)
Interest expense	(362)	(54)	(851)	(73)
Income (loss) before income taxes and noncontrolling interest	(3,568)	(2,414)	(11,883)	(1,832)
Income tax expense (benefit)	(927)	(554)	(2,849)	(649)
Net income	(2,641)	(1,860)	(9,034)	(1,183)
Less net income (loss) attributable to non controlling interests	(439)	(187)	(1,085)	792
Net income attributable to LHC Group, Inc.’s common stockholders	(2,202)	(1,673)	(7,949)	(1,975)
Total assets	80,223	83,276	80,223	83,276
HCI
Segment Reporting, Disclosure of Entity's Reportable Segments [Abstract]
Net service revenue	20,360	17,884	30,945	29,795
Cost of service revenue (excluding depreciation and amortization)	2,755	3,281	8,667	9,720
General and administrative expenses	6,624	4,387	13,674	10,199
Impairment of intangibles and other	0		0	0
Operating income	10,981	10,216	8,604	9,876
Interest expense	(180)	(22)	(387)	(31)
Income (loss) before income taxes and noncontrolling interest	10,801	10,194	8,217	9,845
Income tax expense (benefit)	2,774	2,522	2,129	2,445
Net income	8,027	7,672	6,088	7,400
Less net income (loss) attributable to non controlling interests	160	(6)	150	(37)
Net income attributable to LHC Group, Inc.’s common stockholders	7,867	7,678	5,938	7,437
Total assets	$ 79,972	$ 75,334	$ 79,972	$ 75,334

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Millions	9 Months Ended
Income Taxes (Details) - USD ($) $ in Millions	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Excess tax benefits associated with stock-based compensation arrangements	$ 0.9	$ 2.4
Unrecognized tax benefits	$ 8		$ 7.3

Subsequent Event (Details)

Subsequent Event (Details) - Home Health Agency - Subsequent Event $ in Millions	Oct. 01, 2022 USD ($) acquisition
Subsequent Event [Line Items]
Number of businesses acquired \| acquisition	3
Consideration transferred \| $	$ 18.5